<article article-type="article" specific-use="production" xml:lang="en" xmlns:hw="org.highwire.hpp" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:ref="http://schema.highwire.org/Reference" xmlns:hwp="http://schema.highwire.org/Journal" xmlns:l="http://schema.highwire.org/Linking" xmlns:r="http://schema.highwire.org/Revision" xmlns:x="http://www.w3.org/1999/xhtml" xmlns:app="http://www.w3.org/2007/app" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nlm="http://schema.highwire.org/NLM/Journal" xmlns:a="http://www.w3.org/2005/Atom" xmlns:c="http://schema.highwire.org/Compound" xmlns:hpp="http://schema.highwire.org/Publishing"><front><journal-meta><journal-id journal-id-type="hwp">biorxiv</journal-id><journal-id journal-id-type="publisher-id">BIORXIV</journal-id><journal-title>bioRxiv</journal-title><abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title><publisher><publisher-name>Cold Spring Harbor Laboratory</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1101/241075</article-id><article-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;241075v2</article-id><article-id pub-id-type="other" hwp:sub-type="pisa-master">biorxiv;241075</article-id><article-id pub-id-type="other" hwp:sub-type="slug">241075</article-id><article-id pub-id-type="other" hwp:sub-type="tag">241075</article-id><article-version>1.2</article-version><article-categories><subj-group subj-group-type="author-type"><subject>Regular Article</subject></subj-group><subj-group subj-group-type="heading"><subject>New Results</subject></subj-group><subj-group subj-group-type="hwp-journal-coll" hwp:journal-coll-id="Evolutionary Biology" hwp:journal="biorxiv"><subject>Evolutionary Biology</subject></subj-group></article-categories><title-group><article-title hwp:id="article-title-1">Pervasive and diverse collateral sensitivity profiles inform optimal strategies to limit antibiotic resistance</article-title></title-group><author-notes hwp:id="author-notes-1"><fn id="n1" hwp:id="fn-1" hwp:rev-id="xref-fn-1-1"><label>a</label><p hwp:id="p-1">Electronic mail: <email hwp:id="email-1">kbwood@umich.edu</email></p></fn></author-notes><contrib-group hwp:id="contrib-group-1"><contrib contrib-type="author" hwp:id="contrib-1"><name name-style="western" hwp:sortable="Maltas Jeff"><surname>Maltas</surname><given-names>Jeff</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-1" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-2"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0985-7401</contrib-id><name name-style="western" hwp:sortable="Wood Kevin B."><surname>Wood</surname><given-names>Kevin B.</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-2" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-1" hwp:rel-id="aff-2">2</xref><xref ref-type="fn" rid="n1" hwp:id="xref-fn-1-1" hwp:rel-id="fn-1">a</xref><object-id pub-id-type="other" hwp:sub-type="orcid" xlink:href="http://orcid.org/0000-0002-0985-7401"/></contrib><aff id="a1" hwp:id="aff-1" hwp:rev-id="xref-aff-1-1 xref-aff-1-2"><label>1</label><institution hwp:id="institution-1">Department of Biophysics, University of Michigan</institution>, Ann Arbor, MI 48109</aff><aff id="a2" hwp:id="aff-2" hwp:rev-id="xref-aff-2-1"><label>2</label><institution hwp:id="institution-2">Department of Physics, University of Michigan</institution>, Ann Arbor, MI 48109</aff></contrib-group><pub-date pub-type="epub-original" hwp:start="2018"><year>2018</year></pub-date><pub-date pub-type="hwp-created" hwp:start="2017-12-30T10:24:16-08:00">
    <day>30</day><month>12</month><year>2017</year>
  </pub-date><pub-date pub-type="hwp-received" hwp:start="2018-01-02T12:33:27-08:00">
    <day>2</day><month>1</month><year>2018</year>
  </pub-date><pub-date pub-type="epub" hwp:start="2017-12-30T10:29:55-08:00">
    <day>30</day><month>12</month><year>2017</year>
  </pub-date><pub-date pub-type="epub-version" hwp:start="2018-01-02T12:40:02-08:00">
    <day>2</day><month>1</month><year>2018</year>
  </pub-date><elocation-id>241075</elocation-id><history hwp:id="history-1">
<date date-type="received" hwp:start="2017-12-29"><day>29</day><month>12</month><year>2017</year></date>
<date date-type="rev-recd" hwp:start="2018-01-02"><day>02</day><month>1</month><year>2018</year></date>
<date date-type="accepted" hwp:start="2018-01-02"><day>02</day><month>1</month><year>2018</year></date>
</history><permissions><copyright-statement hwp:id="copyright-statement-1">© 2018, Posted by Cold Spring Harbor Laboratory</copyright-statement><copyright-year>2018</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" hwp:id="license-1"><p hwp:id="p-2">This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at <ext-link l:rel="related" l:ref-type="uri" l:ref="http://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" hwp:id="ext-link-1">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></p></license></permissions><self-uri xlink:href="241075.pdf" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/abstract" xlink:role="abstract" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:href="file:/content/biorxiv/vol0/issue2019/pdf/241075v2.pdf" hwp:variant="yes" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:role="full-text" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/source" xlink:role="source" content-type="xml" xlink:show="none" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/original" xlink:role="original" content-type="xml" xlink:show="none" hwp:variant="yes" xlink:href="241075.xml"/><self-uri content-type="abstract" xlink:href="file:/content/biorxiv/vol0/issue2019/abstracts/241075v2/241075v2.htslp"/><self-uri content-type="fulltext" xlink:href="file:/content/biorxiv/vol0/issue2019/fulltext/241075v2/241075v2.htslp"/><abstract hwp:id="abstract-1"><p hwp:id="p-3">The growing threat of drug resistance has inspired a surge in evolution-based strategies for optimizing the efficacy of antibiotics. One promising approach involves harnessing collateral sensitivity–the increased susceptibility to one drug accompanying resistance to a different drug–to mitigate the spread of resistance. Unfortunately, because the mechanisms of collateral sensitivity are diverse and often poorly understood, the systematic design of multi-drug treatments based on these evolutionary trade-offs is extraordinarily difficult. In this work, we provide an extensive phenotypic characterization of collateral drug effects in <italic toggle="yes">E. faecalis</italic>, a gram-positive species among the leading causes of nosocomial infections. By combining parallel experimental evolution with high-throughput dose-response measurements, we provide quantitative profiles of collateral sensitivity and resistance for a total of 900 mutant-drug combinations. We find that collateral effects are pervasive but difficult to predict, as even mutants selected by the same drug can exhibit qualitatively different profiles of collateral sensitivity. Overall, variability in collateral profiles is strongly correlated with the final level of resistance to the selecting drug. In addition, collateral effects to certain drugs (e.g. ceftriaxone) are considerably more variable than those to other drugs (e.g. fosfomycin), even for drugs from the same class. Remarkably, however, the sensitivity profiles cluster into statistically similar groups characterized by selecting drugs with similar mechanisms. To exploit the underlying statistical structure in the collateral profiles, we develop a simple mathematical framework based on a Markov decision process (MDP) to identify optimal antibiotic cycling policies that maximize expected collateral sensitivity. Importantly, these cycles can be tuned to optimize long-term treatment outcomes, leading to drug sequences that may produce long-term collateral sensitivity at the expense of short-term collateral resistance.</p></abstract><counts><page-count count="24"/></counts><custom-meta-wrap>
    <custom-meta hwp:id="custom-meta-1">
      <meta-name>has-earlier-version</meta-name>
      <meta-value>yes</meta-value>
    </custom-meta>
  </custom-meta-wrap></article-meta></front><body><sec id="s1" hwp:id="sec-1"><label>I.</label><title hwp:id="title-1">INTRODUCTION</title><p hwp:id="p-4">The rapid emergence of drug resistance is an urgent threat to effective treatments for bacterial infections, cancers and many viral infections<sup><xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-1" hwp:rel-id="ref-1">1</xref>–<xref ref-type="bibr" rid="c6" hwp:id="xref-ref-6-1" hwp:rel-id="ref-6">6</xref></sup>. Unfortunately, the development of novel drugs is a long and arduous process, underscoring the need for alternative approaches to forestall resistance evolution. Recent work has highlighted the promise of evolution-based strategies for optimizing and prolonging the efficacy of established drugs, including optimal dose scheduling<sup><xref ref-type="bibr" rid="c7" hwp:id="xref-ref-7-1" hwp:rel-id="ref-7">7</xref>–<xref ref-type="bibr" rid="c9" hwp:id="xref-ref-9-1" hwp:rel-id="ref-9">9</xref></sup>, antimicrobial stewardship<sup><xref ref-type="bibr" rid="c10" hwp:id="xref-ref-10-1" hwp:rel-id="ref-10">10</xref>,<xref ref-type="bibr" rid="c11" hwp:id="xref-ref-11-1" hwp:rel-id="ref-11">11</xref></sup>, drug cycling<sup><xref ref-type="bibr" rid="c12" hwp:id="xref-ref-12-1" hwp:rel-id="ref-12">12</xref>–<xref ref-type="bibr" rid="c14" hwp:id="xref-ref-14-1" hwp:rel-id="ref-14">14</xref></sup>, consideration of spatial dynamics<sup><xref ref-type="bibr" rid="c15" hwp:id="xref-ref-15-1" hwp:rel-id="ref-15">15</xref>,<xref ref-type="bibr" rid="c16" hwp:id="xref-ref-16-1" hwp:rel-id="ref-16">16</xref></sup>, cooperative dynamics<sup><xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-1" hwp:rel-id="ref-17">17</xref>–<xref ref-type="bibr" rid="c20" hwp:id="xref-ref-20-1" hwp:rel-id="ref-20">20</xref></sup>, or phenotypic resistance<sup><xref ref-type="bibr" rid="c21" hwp:id="xref-ref-21-1" hwp:rel-id="ref-21">21</xref>–<xref ref-type="bibr" rid="c23" hwp:id="xref-ref-23-1" hwp:rel-id="ref-23">23</xref></sup>, and judicious use of drug combinations<sup><xref ref-type="bibr" rid="c24" hwp:id="xref-ref-24-1" hwp:rel-id="ref-24">24</xref>–<xref ref-type="bibr" rid="c31" hwp:id="xref-ref-31-1" hwp:rel-id="ref-31">31</xref></sup>. In a similar spirit, a number of recent studies have suggested exploiting collateral sensitivity as a means for slowing or even reversing antibiotic resistance<sup><xref ref-type="bibr" rid="c32" hwp:id="xref-ref-32-1" hwp:rel-id="ref-32">32</xref>–<xref ref-type="bibr" rid="c35" hwp:id="xref-ref-35-1" hwp:rel-id="ref-35">35</xref></sup>. Collateral evolution occurs when a population evolves resistance to a target drug while simultaneously exhibiting increased sensitivity or resistance to a different drug. From an evolutionary perspective, collateral effects are reminiscent of the trade-offs inherent when organisms are required to simultaneously adapt to different tasks, an optimization that is often surprisingly simple because it takes place on a low-dimensional phenotypic space<sup><xref ref-type="bibr" rid="c36" hwp:id="xref-ref-36-1" hwp:rel-id="ref-36">36</xref>,<xref ref-type="bibr" rid="c37" hwp:id="xref-ref-37-1" hwp:rel-id="ref-37">37</xref></sup>. If similarly tractable dynamics occur in the evolution of multi-drug resistance, systematic optimization of drug deployment has the promise to mitigate the effects of resistance.</p><p hwp:id="p-5">Indeed, recent studies in bacteria have shown that the cyclic<sup><xref ref-type="bibr" rid="c38" hwp:id="xref-ref-38-1" hwp:rel-id="ref-38">38</xref>–<xref ref-type="bibr" rid="c40" hwp:id="xref-ref-40-1" hwp:rel-id="ref-40">40</xref></sup> or simultaneous<sup><xref ref-type="bibr" rid="c41" hwp:id="xref-ref-41-1" hwp:rel-id="ref-41">41</xref></sup> deployment of antibiotics with mutual collateral sensitivity can sometimes slow the emergence of resistance. Unfortunately, collateral profiles have also been shown to be highly hetero-geneous<sup><xref ref-type="bibr" rid="c42" hwp:id="xref-ref-42-1" hwp:rel-id="ref-42">42</xref>,<xref ref-type="bibr" rid="c43" hwp:id="xref-ref-43-1" hwp:rel-id="ref-43">43</xref></sup> and often not repeatable<sup><xref ref-type="bibr" rid="c44" hwp:id="xref-ref-44-1" hwp:rel-id="ref-44">44</xref></sup>, potentially complicating the design of successful collateral sensitivity cycles. The picture that emerges is enticing, but complex; while collateral effects offer a promising new dimension for optimizing therapies, the ultimate success of these approaches will require quantitative and predictive understanding of both the prevalence and repeatability of collateral sensitivity profiles across species.</p><p hwp:id="p-6">In this work, we provide an extensive quantitative look at collateral drug effects in <italic toggle="yes">E. faecalis</italic>, a gram-positive species often implicated in nosocomial infections, including bacteremia, native and prosthetic valve endocarditis, and medical device infections<sup><xref ref-type="bibr" rid="c45" hwp:id="xref-ref-45-1" hwp:rel-id="ref-45">45</xref>–<xref ref-type="bibr" rid="c48" hwp:id="xref-ref-48-1" hwp:rel-id="ref-48">48</xref></sup>. By combining parallel experimental evolution of <italic toggle="yes">E. faecalis</italic> with high-throughput dose-response measurements, we provide collateral sensitivity and resistance profiles for 60 strains evolved to 15 different antibiotics, yielding a total of 900 mutant-drug combinations. We find that collateral resistance and collateral sensitivity are pervasive in drug-resistant mutants, though patterns of collateral effects can vary significantly, even for mutants evolved to the same drug. Variability in collateral profiles is correlated with the final level of resistance to the selecting drug. In addition, collateral effects to certain drugs (e.g. ceftriaxone) are considerably more variable than those to other drugs (fosfomycin), even for drugs from the same class. Remarkably, however, the sensitivity profiles cluster into groups characterized by selecting drugs from similar drug classes, indicating the existence of large scale statistical structure in the collateral sensitivity network. Finally, we develop a simple mathematical framework based on Markov Decision Processes (MDP) to identify optimal antibiotic cycling policies that maximize expected collateral sensitivity. These cycles can be tuned to optimize either short-term or long-term evolutionary outcomes and yield strikingly different protocols depending on the time horizon for treatment.</p></sec><sec id="s2" hwp:id="sec-2"><label>II.</label><title hwp:id="title-2">RESULTS</title><sec id="s2a" hwp:id="sec-3"><label>A.</label><title hwp:id="title-3">Collateral effects are pervasive and heterogeneous</title><p hwp:id="p-7">To investigate collateral drug effects in <italic toggle="yes">E. faecalis</italic>, we exposed four independent populations of strain V583 to increasing concentrations of a single drug over 8 days (approximately 60 generations) using serial passage laboratory evolution (<xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-1" hwp:rel-id="F1">Figure 1A</xref>, Methods). We repeated this evolution for a total of 15 commonly used antibiotics spanning a wide range of clinically relevant classes and mechanisms of action (<xref ref-type="table" rid="tbl1" hwp:id="xref-table-wrap-1-1" hwp:rel-id="T1">Table 1</xref>). After approximately 60 generations, we isolated a single colony from each population and measured its response to all 15 drugs using replicate dose-response experiments (<xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-2" hwp:rel-id="F1">Figure 1B</xref>). To quantify resistance, we estimated the half maximal inhibitory concentration (IC<sub>50</sub>) for each mutant-drug combination using nonlinear least squares fitting to a Hill-like dose response function (Methods; see Figure S1 for examples). A mutant strain was deemed collaterally sensitive (resistant) to an antibiotic if its IC<sub>50</sub> decreased (increased) by more than <italic toggle="yes">3σ<sub>WT</sub></italic>, where <italic toggle="yes">σ<sub>WT</sub></italic> is the uncertainty (standard error across replicates) of the IC<sub>50</sub> measured in the wild-type strain. As a measure of collateral resistance / sensitivity, we then calculate <italic toggle="yes">C</italic> = log<sub>2</sub> (IC<sub>50,</sub><italic toggle="yes"><sub>Mut</sub></italic>/IC<sub>50,</sub><italic toggle="yes"><sub>WT</sub></italic>), the (log-scaled) fold change in IC<sub>50</sub> of each mutant relative to wild-type (WT); values of <italic toggle="yes">C</italic> &gt; 0 indicate collateral resistance, while values of <italic toggle="yes">C</italic> &lt; 0 indicate collateral sensitivity (<xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-3" hwp:rel-id="F1">Figure 1C</xref>). For each mutant, we refer to the set of 15 <italic toggle="yes">C</italic> values (one for each testing drug) as its collateral sensitivity profile <inline-formula hwp:id="inline-formula-1"><alternatives hwp:id="alternatives-1"><inline-graphic xlink:href="241075_inline1.gif" hwp:id="inline-graphic-1"/></alternatives></inline-formula>.</p><table-wrap id="tbl1" orientation="portrait" position="float" hwp:id="T1" hwp:rev-id="xref-table-wrap-1-1 xref-table-wrap-1-2"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;241075v2/TBL1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T1</object-id><object-id pub-id-type="publisher-id">tbl1</object-id><label>TABLE I.</label><caption hwp:id="caption-1"><p hwp:id="p-8">Table of antibiotics used in this study and their targets.</p></caption><graphic xlink:href="241075_tbl1" position="float" orientation="portrait" hwp:id="graphic-1"/></table-wrap><fig id="fig1" position="float" orientation="portrait" fig-type="figure" hwp:id="F1" hwp:rev-id="xref-fig-1-1 xref-fig-1-2 xref-fig-1-3 xref-fig-1-4 xref-fig-1-5 xref-fig-1-6 xref-fig-1-7 xref-fig-1-8 xref-fig-1-9 xref-fig-1-10"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;241075v2/FIG1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F1</object-id><object-id pub-id-type="publisher-id">fig1</object-id><label>FIG. 1.</label><caption hwp:id="caption-2"><title hwp:id="title-4">Collateral effects are pervasive and vary across parallel evolution experiments in <italic toggle="yes">E. faecalis</italic>. A. <italic toggle="yes">E</italic>.</title><p hwp:id="p-9"><italic toggle="yes">faecalis</italic> strain V583 was exposed to increasing concentrations of a single antibiotic over an 8-day serial passage experiment with daily 200-fold dilutions (≈60 generations total; see Methods). The evolution was performed in quadruplicate for each drug and repeated for a total of 15 drugs. After 8 days, a single mutant was isolated from each population. B. The half maximal inhibitory concentration (IC50) for each of 15 drugs was estimated for all 60 mutants by nonlinear fitting of a dose response curve (relative OD) to a Hill-like function (Methods). C. Main panel: resistance (red) or sensitivity (green) of each evolved mutant (horizontal axis; 15 drugs x 4 mutants per drug) to each drug (vertical axis) is quantified by the log<sub>2</sub>-transformed relative increase in the IC<sub>50</sub> of the testing drug relative to that of wild-type (V583) cells. While the color scale ranges from a 4x decrease to a 4x increase in IC<sub>50</sub>, it should be noted that both resistance to the selecting drug (diagonal blocks) and collateral effects can be significantly higher. Each column of the heat map represents a collateral sensitivity profile for one mutant. Bottom panel: enlarged (and rotated) column from main panel. Mutants isolated from replicate populations evolved to daptomcyin exhibit diverse sensitivity profiles. While all mutants are resistant to the selecting drug (daptomycin), mutants may exhibit either sensitivity or resistance to other drugs. For example, replicates 1 and 4 exhibit collateral resistance to ceftriaxone (cef), while replicate 2 exhibits collateral sensitivity and replicate 3 shows little effect.</p></caption><graphic xlink:href="241075_fig1" position="float" orientation="portrait" hwp:id="graphic-2"/></fig><p hwp:id="p-10">Our results indicate that collateral effects–including sensitivity–are pervasive, with approximately 73 percent (612/840) of all (collateral) drug-mutant combinations exhibiting a statistically significant change in IC<sub>50</sub>. The mutants in our study exhibit collateral sensitivity to a median of 4 drugs, with only 3 of the 60 mutants (5 percent) exhibiting no collateral sensitivity at all; by contrast, mutants selected by ceftriaxone (cef) and fosfomycin (fos) exhibit particularly widespread collateral sensitivity. Collateral resistance is similarly prevalent, with only 2 strains failing to exhibit collateral resistance to at least one drug. Somewhat surprisingly, 56 of 60 mutants exhibit collateral resistance to at least one drug from a different class (e.g. all mutants evolved to ciprofloxacin, a DNA synthesis inhibitor, show increased resistance ceftriaxone, an inhibitor of cell wall synthesis).</p><p hwp:id="p-11">In addition, collateral effects can be quite large. For example, we measure 8 instances of collateral sensitivity where the IC<sub>50</sub> decreases by 16 fold or more. We also observe a strong, repeatable collateral sensitivity to rifampicin when mutants were selected by inhibitors of cell wall synthesis, an effect that–to our knowledge–has not been reported elsewhere. More typically, however, collateral effects are smaller than the direct effects to the selecting drug, with 46 percent (384/840) exhibiting more than a factor 2 change in IC<sub>50</sub> and only 7 percent (61/840) exhibiting more than a factor 4 change.</p></sec><sec id="s2b" hwp:id="sec-4"><label>B.</label><title hwp:id="title-5">Variation in collateral profiles is correlated with resistance to selecting drug and prevalence of large collateral effects to testing drug</title><p hwp:id="p-12">Our results also indicate that collateral profiles can vary significantly even when mutants are evolved in parallel to the same drug (<xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-4" hwp:rel-id="F1">Figure 1C</xref>). For example, all 4 mutants selected by daptomycin exhibit high-level resistance to the selecting drug, but replicates 1 and 4 exhibit collateral resistance to ceftriaxone (cef), while replicate 2 exhibits collateral sensitivity and replicate 3 shows little effect (<xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-5" hwp:rel-id="F1">Figure 1C</xref>, bottom panel).</p><p hwp:id="p-13">To quantify the variation between replicates selected by the same drug, we viewed the collateral profile of each mutant (i.e. a column of the collateral sensitivity matrix in <xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-6" hwp:rel-id="F1">Figure 1</xref>) as a vector in 15-dimensional drug resistance space. Then, for each set of replicates, we defined the variability <inline-formula hwp:id="inline-formula-2"><alternatives hwp:id="alternatives-2"><inline-graphic xlink:href="241075_inline2.gif" hwp:id="inline-graphic-2"/></alternatives></inline-formula>, where <italic toggle="yes">m</italic> = 4 is the number of replicates and <italic toggle="yes">d<sub>i</sub></italic> is the Euclidean distance between mutant <italic toggle="yes">i</italic> and the centroid formed by all vectors corresponding to a given selecting drug (<xref ref-type="fig" rid="fig2" hwp:id="xref-fig-2-1" hwp:rel-id="F2">Figure 2A</xref>). Variability differs for different selecting drugs, with daptomycin and rifampicin showing the largest variability and nitrofurantoin the smallest (<xref ref-type="fig" rid="fig2" hwp:id="xref-fig-2-2" hwp:rel-id="F2">Figure 2B</xref>). Interestingly, we find that the observed variability is significantly correlated with average resistance to the selecting drug (Figure S2). This correlation persists even when one removes contributions to variability from the selecting drug (<xref ref-type="fig" rid="fig2" hwp:id="xref-fig-2-3" hwp:rel-id="F2">Figure 2C</xref>), indicating that collateral (rather than direct) effects underlie the correlation. We do note, however, that selection by spectinomcyin represents a notable exception to this trend.</p><fig id="fig2" position="float" orientation="portrait" fig-type="figure" hwp:id="F2" hwp:rev-id="xref-fig-2-1 xref-fig-2-2 xref-fig-2-3 xref-fig-2-4 xref-fig-2-5"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;241075v2/FIG2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F2</object-id><object-id pub-id-type="publisher-id">fig2</object-id><label>FIG. 2.</label><caption hwp:id="caption-3"><title hwp:id="title-6">Variation in collateral profiles is correlated with resistance to selecting drug and prevalence of large collateral effects to testing drug.</title><p hwp:id="p-14">A. Variability in collateral profiles between mutants selected by the same drug is defined by first representing each mutant’s collateral profile as a vector <inline-formula hwp:id="inline-formula-3"><alternatives hwp:id="alternatives-3"><inline-graphic xlink:href="241075_inline3.gif" hwp:id="inline-graphic-3"/></alternatives></inline-formula> in 15-dimensional drug space. Dimension <italic toggle="yes">i</italic> represents the log<sub>2</sub>-scaled fold increase in IC<sub>50</sub> (relative to wild-type) for drug <italic toggle="yes">i</italic>. The variability for a set of mutants evolved to the same drug is then given by the average Euclidean distance <italic toggle="yes">d<sub>i</sub></italic> for a mutant from the centroid. B. Variability in replicates (defined in panel A) for all 15 drugs used for selection. C. Scatter plot between the variability calculated in (B)–now with effects of selecting drug removed–and the (log<sub>2</sub>-scaled) fold increase in IC<sub>50</sub> to the selecting drug (Spearman correlation of 0.58, <italic toggle="yes">p =</italic> 0.03 including the spc mutants; 0.82, p &lt; 10<sup>−3</sup> without the spc mutants.). To remove effects from the selecting drug, variability is calculated in the 14-dimensional space defined by removing the selecting drug. D. Main panel: heatmap of variance in resistance level (log<sub>2</sub>-scaled fold increase in IC<sub>50</sub> relative to wild-type) across populations selected by the same drug. Right panel: mean variance to each selecting drug (mean across rows in heatmap). E. Scatter plot between mean variance (calculated in D) and the fraction of all mutants exhibiting large collateral effects. A large collateral effect is defined to be a change in resistance to a non-selecting drug leading to a greater than 2-fold change in IC<sub>50</sub> (Spearman correlation 0.84). Inset: expanded view of main plot. Dashed line: best linear fit (excluding ceftriaxone mutants).</p></caption><graphic xlink:href="241075_fig2" position="float" orientation="portrait" hwp:id="graphic-3"/></fig><p hwp:id="p-15">While resistance to the selecting drug is correlated with profile variability, it is not clear whether a similar relationship exists between repeatability (across replicates) and certain testing drugs. To investigate this question, we calculated the variance of <italic toggle="yes">C</italic> (see <xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-7" hwp:rel-id="F1">Figure 1C</xref>) across replicates for each combination of selecting and testing drug (<xref ref-type="fig" rid="fig2" hwp:id="xref-fig-2-4" hwp:rel-id="F2">Figure 2D</xref>). We find that the majority of the variance values are less than 0.5, through rare instances of larger variance occur. To determine whether variance is related to the drug used for testing, we calculated the mean variance across all selecting drugs (<xref ref-type="fig" rid="fig2" hwp:id="xref-fig-2-5" hwp:rel-id="F2">Figure 2D</xref>, right panel). Interestingly, the average variance for some drugs (most notably ceftriaxone) is considerably higher than for others (e.g. fosfomycin), and this variance is strongly correlated with the prevalence of large collateral effects (i.e. the fraction of mutants exhibiting greater than 2-fold change in IC<sub>50</sub>). Notably, however, the collateral effects to ceftriaxone and fosfomycin are qualitatively (direction-wise) almost identical, despite the large differences in magnitude.</p><p hwp:id="p-16">Overall, these results suggest that the repeatability of collateral effects is sensitive to both the drug used for selection and the drug used for testing. As a result, certain drugs may be more appropriate for establishing robust antibiotic cycling profiles.</p></sec><sec id="s2c" hwp:id="sec-5"><label>C.</label><title hwp:id="title-7">Collateral Resistance Threatens the Efficacy of Daptomycin</title><p hwp:id="p-17">Daptomycin is a lipopeptide antibiotic that is often used as a last line of defense against gram-positive bacterial infections, including vancomycin resistant enterococcus (VRE). While daptomycin resistance was initially believed to be quite rare<sup><xref ref-type="bibr" rid="c49" hwp:id="xref-ref-49-1" hwp:rel-id="ref-49">49</xref></sup>, it has become increasingly documented in clinical settings<sup><xref ref-type="bibr" rid="c50" hwp:id="xref-ref-50-1" hwp:rel-id="ref-50">50</xref></sup>. Given the clinical importance of daptomycin, it is perhaps surprising that resistance to daptomycin is particularly common when populations are selected by other antibiotics. Specifically, we found that 66 percent of all evolved lineages display collateral resistance to daptomycin, while only 9 percent of lineages display collateral sensitivity (<xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-1" hwp:rel-id="F3">Figure 3A</xref>).</p><fig id="fig3" position="float" orientation="portrait" fig-type="figure" hwp:id="F3" hwp:rev-id="xref-fig-3-1 xref-fig-3-2 xref-fig-3-3 xref-fig-3-4"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;241075v2/FIG3</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F3</object-id><object-id pub-id-type="publisher-id">fig3</object-id><label>FIG. 3.</label><caption hwp:id="caption-4"><title hwp:id="title-8">Collateral resistance threatens the efficacy of daptomycin and can magnify resistance to chloramphenicol.</title><p hwp:id="p-18">A. Estimated dose response curves (fit to Hill-like function) for all mutants tested against daptomycin. Strains evolved to daptomycin (blue) and all other drugs (red) frequently exhibit increased resistance to daptomycin relative to wildtype (black, individual replicates; dotted green line, mean IC<sub>50</sub>). Right inset: Approximately 66 percent of all drug-evolved mutants exhibit increased daptomycin resistance, while only 9 percent exhibit collateral sensitivity. B. Fractional change in chloramphenicol (cam) IC<sub>50</sub> for mutants evolved to linezolid (blue). The width of the green line represents the confidence interval (± 3 standard errors of the mean measured over 8 replicate measurements) for the (normalized) choramphenicol IC<sub>50</sub> in wild-type cells. For comparison, the red lines represent the final (day 8) cam resistance achieved in populations evolved directly to cam. Inset: Schematic depicting two paths to different cam resistance maximums. The green circle represents the sensitive wild-type. Evolution can occur to cam directly (red line) or to cam collaterally through lin resistance (blue line). The lin evolution depicts early collateral sensitivity before ultimately achieving a higher total resistance.</p></caption><graphic xlink:href="241075_fig3" position="float" orientation="portrait" hwp:id="graphic-4"/></fig><fig id="fig4" position="float" orientation="portrait" fig-type="figure" hwp:id="F4"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;241075v2/FIG4</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F4</object-id><object-id pub-id-type="publisher-id">fig4</object-id><label>FIG. 4.</label><caption hwp:id="caption-5"><title hwp:id="title-9">Hierarchical clustering of collateral sensitivity profiles partitions mutants into groups selected by known drug classes</title><p hwp:id="p-19">A. Each circle represents a single mutant. Color depicts drug used for selection. Low-level clustering is largely characterized by grouping of mutants evolved to the same drug (i.e. replicate evolution experiments). However, in several cases mutants selected by one drug (e.g. tigecycline, Tig) cluster with mutants selected by a different drug (doxycycline, Dx) of the same class. B. At later stages of clustering, mutants evolved to drugs from a similar class–or with similar mechanisms of action– tend to cluster together.</p></caption><graphic xlink:href="241075_fig4" position="float" orientation="portrait" hwp:id="graphic-5"/></fig></sec><sec id="s2d" hwp:id="sec-6"><label>D.</label><title hwp:id="title-10">Selection by linezolid leads to higher chloramphenicol resistance than direct selection by chloramphenicol</title><p hwp:id="p-20">Surprisingly, we found that mutants selected by linezolid (lin) developed higher resistance to chloramphenicol (cam) than mutants selected directly by cam (<xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-2" hwp:rel-id="F3">Figure 3B</xref>). To investigate this phenomenon, we isolated linezolid-selected mutants at days 2, 4, 6 and 8 of the laboratory evolution and measured the resistance of each to chloramphenicol. Interestingly, we see that early-stage (days 4-6) mutants exhibit low level chloramphenicol sensitivity just prior to a dramatic increase in collateral resistance around day 8. These findings suggest linezolid selection drives the population across a chloramphenicol fitness valley, ultimately leading to levels of resistance that exceed those observed by direct chloramphenicol selection (<xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-3" hwp:rel-id="F3">Figure 3B</xref>, inset). While temporally dynamic collateral responses have been recently measured in cancer<sup><xref ref-type="bibr" rid="c43" hwp:id="xref-ref-43-2" hwp:rel-id="ref-43">43</xref>,<xref ref-type="bibr" rid="c51" hwp:id="xref-ref-51-1" hwp:rel-id="ref-51">51</xref></sup>, this represents, to our knowledge, the first evidence of temporally dynamic collateral responses in bacteria.</p></sec><sec id="s2e" hwp:id="sec-7"><label>E.</label><title hwp:id="title-11">Sensitivity profiles cluster into groups based on known classes of selecting drug</title><p hwp:id="p-21">Our results indicate that there is significant heterogeneity in collateral sensitivity profiles, even when parallel populations are selected on the same antibiotic. While the genetic networks underlying these phenotypic responses are complex and, in many cases, poorly understood, one might expect that selection by chemically or mechanistically similar drugs would lead to profiles with shared statistical properties. For example, previous work showed (in a different context) that pairwise interactions between simultaneously applied antibiotics can be used to cluster drugs into groups that interact monochromatically with one another; strikingly, these groups correspond to known drug classes<sup><xref ref-type="bibr" rid="c52" hwp:id="xref-ref-52-1" hwp:rel-id="ref-52">52</xref></sup>, highlighting statistical structure in drug interaction networks that appear, on the surface, to be extremely heterogeneous. Similarly, we asked whether collateral sensitivity profiles can be used to cluster resistant mutants into statistically similar classes. To answer this question, we performed hierarchical clustering on collateral sensitivity profiles for all mutants (52 total) that achieved high-level resistance (at least a mean 2-fold increase in IC<sub>50</sub>) to the selecting drug (Methods; note that we excluded mutants selected by Cam and Nitro, which did not achieve high-level resistance, but we repeated the analysis with those drugs included in Figure S3). Initially, mutants selected by the same drugs or by drugs within the same drug class (e.g. Dox and Tet, Dox and Tig, Lev and Cip, etc) cluster together (<xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-4" hwp:rel-id="F3">Figure 3A</xref>; Figure S4 for dendograms), Strikingly, despite the heterogeneity in collateral profiles, the clustering eventually partitions mutants into groups characterized–almost exclusively–by selecting drugs from established drug classes. For example, inhibitors of cell wall synthesis (amp, ceft, fos, ox) cluster into one group, while tetraclycine-like drugs (tet, dox, tig) cluster into another. At the same time, this analysis does separate some drugs with similar mechanisms (e.g. tetracycline and spectinomycin, both of which target the 30S ribosomal subunits), and it therefore may help identify mechanistically similar drugs likely to generate statistically distinct sensitivity profiles.</p></sec><sec id="s2f" hwp:id="sec-8"><label>F.</label><title hwp:id="title-12">A Markov decision process (MDP) model predicts optimal drug policies</title><p hwp:id="p-22">Our results indicate that collateral sensitivity is pervasive, and while collateral sensitivity profiles are highly heterogeneous, clustering suggests the existence of statistical structure in the data. Nevertheless, because of the stochastic nature of the sensitivity profiles, it is not clear how to best utilize this information to design optimal treatment protocols. To address this problem, we develop a simple mathematical model based on a Markov decision process (MDP) to predict optimal drug cycles. MDP’s are widely used in applied mathematics and finance and have a well-developed theoretical basis<sup><xref ref-type="bibr" rid="c53" hwp:id="xref-ref-53-1" hwp:rel-id="ref-53">53</xref></sup>. In a MDP, a system transitions stochastically between discrete states. Each state is assigned a particular “cost” (or value), and at each time step, we must make a decision (called an “action”) that potentially influences which state will occur next. The goal of the MDP is develop a policy–a set of actions corresponding to each state–that will optimize some objective function (e.g. minimize the expected cost) over some time period.</p><p hwp:id="p-23">For our system, the state <italic toggle="yes">S<sub>t<sub>i</sub></sub></italic> at time step <italic toggle="yes">t<sub>i</sub></italic> = 0,1, 2,… is defined by the collateral sensitivity profile <inline-formula hwp:id="inline-formula-4"><alternatives hwp:id="alternatives-4"><inline-graphic xlink:href="241075_inline5.gif" hwp:id="inline-graphic-4"/></alternatives></inline-formula> describing the current (mutant) population as well as the current drug, <italic toggle="yes">D<sub>t<sub>i</sub></sub></italic>. As in the previous section, we exclude mutants selected by Cam and Nit, which did not achieve high-level resistance to the selecting drug and may therefore be preferentially (and trivially) selected by the optimization algorithm. At each time step, an action <italic toggle="yes">a<sub>t<sub>i</sub></sub></italic> is chosen that determines the drug used at the next time step, <italic toggle="yes">a<sub>t<sub>i</sub></sub></italic> → <italic toggle="yes">D<sub>t<sub>i+1</sub></sub></italic>. The system–which is assumed to be Markovian-then transitions with probability <italic toggle="yes">P</italic>(<italic toggle="yes">S<sub>t<sub>i+1</sub></sub></italic>|<italic toggle="yes">S<sub>t<sub>i</sub></sub></italic>, <italic toggle="yes">a<sub>t<sub>i</sub></sub></italic>) to a new state <italic toggle="yes">S<sub>t<sub>i+1</sub></sub></italic>, and the transition probabilities are estimated from evolutionary experiments (or any available data). The cost function <italic toggle="yes">r<sub>t<sub>i</sub></sub></italic> ≡ <italic toggle="yes">r<sub>t<sub>i</sub></sub></italic>(<italic toggle="yes">S<sub>t<sub>i</sub></sub></italic>) defines a cost associated with each state and can be chosen to represent–for example–the level of collateral sensitivity of the current mutant to the current drug. The optimal policy Π is a mapping Π: <italic toggle="yes">S<sub>t<sub>i</sub></sub></italic> → <italic toggle="yes">a<sub>t<sub>i</sub></sub></italic> from each state to the optimal action (i.e. the optimal next drug). The policy is chosen to minimize <inline-formula hwp:id="inline-formula-5"><alternatives hwp:id="alternatives-5"><inline-graphic xlink:href="241075_inline13.gif" hwp:id="inline-graphic-5"/></alternatives></inline-formula>, where brackets indicate an expectation value conditioned on the initial state <italic toggle="yes">s</italic><sub>0</sub> and the choice of policy Π. The parameter <italic toggle="yes">γ</italic> &lt; 1 is a discount factor that determines the timescale for the optimization; <italic toggle="yes">γ</italic> ≈ 1 leads to long-time optimal solution, while γ ≈ 0 leads to solutions that maximize near-term success.</p><p hwp:id="p-24">To apply the MDP framework to collateral sensitivity profiles, we must infer from our data a set of (stochastic) rules for transitioning between states (i.e. we must estimate <italic toggle="yes">P</italic>(<italic toggle="yes">S<sub>t<sub>i+1</sub></sub></italic>|<italic toggle="yes">S<sub>t<sub>i</sub></sub></italic>, <italic toggle="yes">a<sub>t<sub>i</sub></sub></italic>)). While many choices are possible–and these choices may be refined as additional data is collected–in what follows we consider a simple model where the system can transition only to a state corresponding to one of the four sensitivity profiles experimentally measured under selection to the current drug <italic toggle="yes">D<sub>t<sub>i</sub></sub></italic> (but see Figure S5 and Figure S6 for similar calculations using a model where transitions can occur to <italic toggle="yes">any</italic> sensitivity profile with resistance to the current drug). For example, if the current drug is daptomycin, the sensitivity profile at the next step will be chosen (with uniform probability) to be one of those measured for the four replicates selected by daptomycin (see <xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-8" hwp:rel-id="F1">Figure 1C</xref>, bottom panel). Each time step is therefore assumed to cover approximately 60 generations, similar to the evolution time in our experiments. In addition, this model implicitly assumes sufficiently strong selection that, at each step, the state of the system is fully described by a single collateral sensitivity profile (rather than, for example, a heterogeneous ensemble of profiles that would be required to model clonal interference).</p><p hwp:id="p-25">To maximize the effect of collateral sensitivity, we first choose the cost function <italic toggle="yes">r<sub>t<sub>i</sub></sub></italic> to be −1, 0, or 1 if the profile at the current time step is sensitive to, not affected by, or resistant to the current drug, respectively. Intuitively, the goal is to reward drug choices that lead to sensitivity while punishing those associated with resistance. Interestingly, the drug policy Π that minimizes <italic toggle="yes">R</italic>(<italic toggle="yes">s</italic>) varies significantly depending on the value of <italic toggle="yes">γ</italic>–that is, on the timescale of the optimization (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-1" hwp:rel-id="F5">Figure 5B</xref>). The “instant gratification” policy (<italic toggle="yes">γ</italic> = 0) optimizes short term success and therefore tends to maximize the probability of achieving collateral sensitivity at the next time step (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-2" hwp:rel-id="F5">Figure 5B</xref>, blue circles; Note that because the MDP minimizes cost rather than maximizing probability of sensitivity, even the short-term solution does not always maximize the probability of sensitivity at the next step). On the other hand, the longer term optimization (<italic toggle="yes">γ</italic> = 0.95) may forgo short-term success for longer-term gain.</p><fig id="fig5" position="float" orientation="portrait" fig-type="figure" hwp:id="F5" hwp:rev-id="xref-fig-5-1 xref-fig-5-2 xref-fig-5-3 xref-fig-5-4 xref-fig-5-5 xref-fig-5-6"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;241075v2/FIG5</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F5</object-id><object-id pub-id-type="publisher-id">fig5</object-id><label>FIG. 5.</label><caption hwp:id="caption-6"><title hwp:id="title-13">Drug sequences can be chosen to maximize collateral sensitivity over different timescales.</title><p hwp:id="p-26">A. Schematic: markov decision process (MDP) for maximizing collateral sensitivity. The state <italic toggle="yes">S<sub>t<sub>i</sub></sub></italic> at time step <italic toggle="yes">t<sub>i</sub></italic> is defined by the sensitivity profile of the current mutant and the current drug. The action <italic toggle="yes">a<sub>t<sub>i</sub></sub></italic> that determines the drug at the next time step. The system transitions between states according to the conditional probability <italic toggle="yes">P</italic>(<italic toggle="yes">S<sub>t<sub>i+1</sub></sub></italic>|<italic toggle="yes">S<sub>t<sub>i</sub></sub></italic>, <italic toggle="yes">a<sub>t<sub>i</sub></sub></italic>), which is estimated from lab evolution experiments (e.g. <xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-9" hwp:rel-id="F1">Figure 1</xref>). The cost function <italic toggle="yes">r<sub>t<sub>i</sub></sub></italic> at time <italic toggle="yes">t<sub>i</sub></italic> is either −1, 0, or 1 depending on whether the sensitivity profile shows sensitivity, no effect, or resistance, respectively, to the current drug. The optimal policy n is chosen to minimize <inline-formula hwp:id="inline-formula-6"><alternatives hwp:id="alternatives-6"><inline-graphic xlink:href="241075_inline20.gif" hwp:id="inline-graphic-6"/></alternatives></inline-formula>, where brackets indicate an expectation value conditioned on the initial state s<sub>0</sub> and the choice of policy n. The parameter 0 ≤ <italic toggle="yes">γ</italic> &lt; 1 is a discount factor that determines the timescale for the optimization. B. Heat map indicates the probability of collateral sensitivity to the next drug (rows) given a particular selecting drug (columns). Black stars: optimal short term policy (instant gratification; <italic toggle="yes">γ</italic> = 0)); blue circles: optimal long-term policy (<italic toggle="yes">γ</italic> = 0.95). White squares indicate maximum of each column. C. Left panels: optimal drug cycles, starting from drug 1 (Dap), for long term (upper panel) and instant gratification (lower panel) strategies. Long-term strategy asymptotically approaches a cycle between drugs 5 (Fos), 8 (Tig), and 9 (Spc); the instant gratification strategy approaches a cycle between drug 2 (Amp), 13 (Rif), and 7 (Dox). Right panel: mean collateral effects (cumulative) for the long-term strategy (black), instant gratification strategy (blue), and random drug cycles (red, dashed). The mean collateral effect at time step <italic toggle="yes">t<sub>i</sub></italic> is given by <inline-formula hwp:id="inline-formula-7"><alternatives hwp:id="alternatives-7"><inline-graphic xlink:href="241075_inline21.gif" hwp:id="inline-graphic-7"/></alternatives></inline-formula>, where brackets indicate an average over 1000 independent simulations of the MDP. Here <italic toggle="yes">r<sub>t</sub></italic> is −1, 0, or 1 if the profile at the current time step is sensitive to, not affected by, or resistant to the current drug, respectively.</p></caption><graphic xlink:href="241075_fig5" position="float" orientation="portrait" hwp:id="graphic-6"/></fig><p hwp:id="p-27">For example, if the population is currently exposed to daptomycin, the instant gratification policy prescribes tetracycline as the next drug, which maximizes the probability of collateral sensitivity (i.e. all four mutants selected by daptomycin were sensitive to tetracycline). On the other hand, the long-term optimal policy prescribes rifampicin as the next drug, even though the probability of sensitivity to rifampicin is lower.</p></sec><sec id="s2g" hwp:id="sec-9"><label>G.</label><title hwp:id="title-14">Optimal drug cycles depend on timescale for optimization process</title><p hwp:id="p-28">Once an optimal policy has been found, one can consider a treatment starting from any drug and iteratively determine the sequence of drugs that should follow. Consider a treatment that starts with daptomycin (drug 1). The instant gratification policy leads to a drug sequence of daptomycin (1), tetracycline (6), ampicillin (2), rifampicin (13), and doxycyline (7) before settling into a long-term cycle between the latter 3 drugs (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-3" hwp:rel-id="F5">Figure 5C</xref>, lower left panel). By contrast, the long-term policy leads to a sequence of daptomycin (1) and rifampicin (13) before settling into a long-term cycle between spectinomycin (9), fosfomycin (5), and tigecycle (8) (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-4" hwp:rel-id="F5">Figure 5C</xref>, upper left panel). To compare the expected results of both policies, we simulated the MDP and calculated the mean (cumulative) collateral effect at time step <italic toggle="yes">t<sub>i</sub></italic>, which is given by <inline-formula hwp:id="inline-formula-8"><alternatives hwp:id="alternatives-8"><inline-graphic xlink:href="241075_inline23.gif" hwp:id="inline-graphic-8"/></alternatives></inline-formula>, where brackets indicate an average over 1000 independent simulations of the MDP. While both policies perform significantly better than random drug cycling, the long-term solution leads to the most collateral sensitivity on longer time scales, despite performing worse than the instant gratification on the first time step (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-5" hwp:rel-id="F5">Figure 5C</xref>, right panel).</p></sec><sec id="s2h" hwp:id="sec-10"><label>H.</label><title hwp:id="title-15">Optimal cycles do not always involve drugs with mutual collateral sensitivity</title><p hwp:id="p-29">The cost function in the previous section was chosen to reward collateral sensitivity and punish collateral resistance, but it did not account for the magnitude of the effects. To incorporate these magnitudes, we repeated the MDP analysis with <italic toggle="yes">r<sub>t<sub>i</sub></sub></italic> chosen to be the value <italic toggle="yes">C</italic> of the collateral profile against the current drug. As before, the instant gratification (<italic toggle="yes">γ</italic> = 0) strategy led to a different policy and, in turn, to different optimal cycles than the longterm optimization (<italic toggle="yes">γ</italic> = 0.95). While the instant gratification strategy leads to a long-term cycle between drugs with–on average–mutual collateral sensitivity (<xref ref-type="fig" rid="fig6" hwp:id="xref-fig-6-1" hwp:rel-id="F6">Figure 6</xref>; ceft (4) and rifampicin (13)), the long-term policy involves a cycle between fosfomycin (5) and rifampicin (13), despite the fact that mutants selected by rifampicin do not show appreciable collateral sensitivity to fosfomycin. Intuitively, the long-term optimal makes a single sub-optimal step (rifampicin → fosfomycin)–and one that can sometimes lead to collateral resistance– because the long term cycle between the two drugs is dominated by the large collateral sensitivity imparted by the reverse step (fosfomycin → rifampicin; <xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-6" hwp:rel-id="F5">Figure 5B</xref>, right panel).</p><fig id="fig6" position="float" orientation="portrait" fig-type="figure" hwp:id="F6" hwp:rev-id="xref-fig-6-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;241075v2/FIG6</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F6</object-id><object-id pub-id-type="publisher-id">fig6</object-id><label>FIG. 6.</label><caption hwp:id="caption-7"><title hwp:id="title-16">Maximizing collateral sensitivity values may lead to cycles between drugs without mutual collateral sensitivity.</title><p hwp:id="p-30">A. Heat map indicates the mean value (over replicates) of collateral sensitivity to the next drug (rows) given a particular selecting drug (columns). Black stars: optimal short term policy (instant gratification; γ = 0)); blue circles: optimal long-term policy (γ = 0.95). Red squares indicate minimum of each column. Note that the scale is much larger than in <xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-10" hwp:rel-id="F1">Figure 1</xref> to highlight large sensitivity values relevant for drug cycles. B. Left panels: optimal drug cycles, starting from drug 1 (Dap), for long term (upper panel) and instant gratification (lower panel) strategies. Long-term strategy asymptotically approaches a cycle between drugs 5 (Fos) and 13 (Rif); the instant gratification strategy approaches a cycle between drugs 4 (Cef) and 13 (Rif). Right panel: mean collateral effects (cumulative) for the long-term strategy (black), instant gratification strategy (blue), and random drug cycles (red, dashed). The mean (cumulative) collateral effect at time step <italic toggle="yes">t<sub>i</sub></italic> is given by <inline-formula hwp:id="inline-formula-9"><alternatives hwp:id="alternatives-9"><inline-graphic xlink:href="241075_inline25.gif" hwp:id="inline-graphic-9"/></alternatives></inline-formula>, where brackets indicate an average over 1000 independent simulations of the MDP. Here <italic toggle="yes">r<sub>t</sub></italic> is the value <italic toggle="yes">C</italic> of collateral sensitivity or resistance to the current drug.</p></caption><graphic xlink:href="241075_fig6" position="float" orientation="portrait" hwp:id="graphic-7"/></fig></sec></sec><sec id="s3" hwp:id="sec-11"><label>III.</label><title hwp:id="title-17">DISCUSSION</title><p hwp:id="p-31">Our work provides an extensive quantitative study of phenotypic collateral drug effects in <italic toggle="yes">E. faecalis</italic>. We have shown that collateral resistance and collateral sensitivity are widespread but heterogeneous, with patterns of collateral effects often varying even between mutants evolved to the same drug. Our results contain a number of surprising, drug-specific observations; for example, we observed a strong, repeatable collateral sensitivity to rifampicin when mutants were selected by inhibitors of cell wall synthesis. Additionally, cross-resistance to daptomycin, often viewed as a last line of defense for dangerous clinical infections, is particularly common when cells are selected by other frequently used antibiotics. Because the FDA/CLSI breakpoint for daptomycin resistance is not dramatically different than the MIC distributions found in clinical isolates prior to daptomycin use<sup><xref ref-type="bibr" rid="c54" hwp:id="xref-ref-54-1" hwp:rel-id="ref-54">54</xref></sup>, one may speculate that even small collateral effects could have potentially harmful consequences for clinical treatments involving daptomycin. In addition, we found that selection by one drug (linezolid) led to higher overall resistance to chloramphenicol than direct selection by chloramphenicol, illustrating how indirect selection may drive a population across a fitness valley to an otherwise inaccessible fitness peak.</p><p hwp:id="p-32">Our findings also point to global trends in collateral sensitivity profiles. For example, we found that the repeatability of collateral effects is sensitive to both the drug used for selection and the drug used for testing, meaning that some drugs may be better than others for establishing robust antibiotic cycling profiles. On the other hand, despite the apparent unpredictability of collateral effects at the level of individual mutants, the sensitivity profiles for mutants selected by drugs from known classes tend to cluster into statistically similar groups. The clustering also points to systematic differences between phenotypes exhibiting resistance to some drugs (e.g. tetracycline and spectinomycin) with similar mechanisms of action; the process therefore provides a powerful functional classification of drugs that complements known molecular mechanisms and may, in the long term, inform clinical decisions about drug choices. In addition, clustering may help to characterize sensitivity profiles of new chemotherapeutic agents even without detailed molecular information on potential resistance mechanisms. Finally, we show how these profiles can be incorporated into a rigorous MDP framework that optimizes drug cycling protocols while accounting for effects of both stochasticity and different time horizons. Within this framework, cycling protocols can be tuned to optimize either short-term or long-term evolutionary outcomes, leading to dramatically different drug sequences.</p><p hwp:id="p-33">Our results complement recent studies on collateral sensitivity and also raise a number of new questions for future work. First, several previous studies have indicated that cycles involving mutually collaterally sensitive drugs may be chosen to harness collateral sensitivity and minimize the evolution of resistance<sup><xref ref-type="bibr" rid="c38" hwp:id="xref-ref-38-2" hwp:rel-id="ref-38">38</xref>,<xref ref-type="bibr" rid="c39" hwp:id="xref-ref-39-1" hwp:rel-id="ref-39">39</xref></sup>. In the context of our MDP model, these cycles would correspond to a type of short-time-horizon optimization similar to our “instant gratification” strategy. Interestingly, however, our results indicate that considering longer time horizons can lead to cycles involving at least one sub-optimal step, including one to a collaterally resistant state. In addition, recent work has highlighted that collateral profiles are heterogeneous<sup><xref ref-type="bibr" rid="c42" hwp:id="xref-ref-42-2" hwp:rel-id="ref-42">42</xref>,<xref ref-type="bibr" rid="c43" hwp:id="xref-ref-43-3" hwp:rel-id="ref-43">43</xref></sup>, and optimization will therefore require incorporation of stochastic effects such as likelihood scores<sup><xref ref-type="bibr" rid="c44" hwp:id="xref-ref-44-2" hwp:rel-id="ref-44">44</xref></sup>. These likelihood scores could potentially inform transition probabilities in our MDP approach, leading to specific predictions for optimal drug sequences.</p><p hwp:id="p-34">Overall, the success of the approach will rely on robust inference of clinically-relevant model parameters–such as transition probabilities–and a careful choice of an appropriate cost function. While in vitro models of pharmacodynamics are often used to inform clinical protocols, it is not clear that in vivo evolutionary trajectories will mimic, in any way, the highly controlled evolution in laboratory environments. Nevertheless, while the current proof-of-principle model is clearly an oversimplification of the evolutionary process, it can be readily expanded to account for more realistic scenarios and to incorporate more complex data sets. Most notably, collateral sensitivity profiles in cancer have been previously shown to be time-dependent<sup><xref ref-type="bibr" rid="c43" hwp:id="xref-ref-43-4" hwp:rel-id="ref-43">43</xref>,<xref ref-type="bibr" rid="c51" hwp:id="xref-ref-51-2" hwp:rel-id="ref-51">51</xref></sup>; our future work will focus on characterizing dynamic properties of collateral effects in <italic toggle="yes">E. faecalis</italic> and expanding the MDP approach to account for time-varying sensitivity profiles. It may also be interesting to investigate collateral effects in <italic toggle="yes">E. faecalis</italic> biofilms, where some classes of antibiotics can have counterintuitive effects even on evolutionarily short timescales<sup><xref ref-type="bibr" rid="c55" hwp:id="xref-ref-55-1" hwp:rel-id="ref-55">55</xref></sup>. On longer timescales, elegant experimental approaches to biofilm evolution have revealed that spatial structure can give rise to rich evolutionary dynamics<sup><xref ref-type="bibr" rid="c56" hwp:id="xref-ref-56-1" hwp:rel-id="ref-56">56</xref>,<xref ref-type="bibr" rid="c57" hwp:id="xref-ref-57-1" hwp:rel-id="ref-57">57</xref></sup>, though to date, little is known about collateral drug effects in these systems.</p><p hwp:id="p-35">Our results also raise questions about the potential molecular and genetic mechanisms underlying the observed collateral effects. While the clustering analysis presented here may point to shared mechanistic explanations for sensitivity profiles selected by similar drugs, uncovering the detailed genetic underpinnings of collateral sensitivity remains an ongoing challenge for future work. At the same time, because our results are based on phenotypic measurements, they may allow for systematic optimization of drug cycling protocols even when molecular mechanisms are not fully known.</p></sec><sec id="s4" hwp:id="sec-12"><label>IV.</label><title hwp:id="title-18">MATERIALS AND METHODS</title><sec id="s4a" hwp:id="sec-13"><label>A.</label><title hwp:id="title-19">Strains, antibiotics and media</title><p hwp:id="p-36">All resistant lineages were derived from <italic toggle="yes">E. faecalis</italic> V583, a fully sequenced vancomycin-resistant clinical isolate<sup><xref ref-type="bibr" rid="c58" hwp:id="xref-ref-58-1" hwp:rel-id="ref-58">58</xref></sup>. The 15 antibiotics used are listed in <xref ref-type="table" rid="tbl1" hwp:id="xref-table-wrap-1-2" hwp:rel-id="T1">Table 1</xref>. Each antibiotic was prepared from powder stock and stored at −20°C with the exception of ampicillin, which was stored at −80°C. Evolution and IC<sub>50</sub> measurements were conducted in BHI medium alone with the exception of daptomycin, which requires an addition of 50 mM calcium for antimicrobial activity.</p></sec><sec id="s4b" hwp:id="sec-14"><label>B.</label><title hwp:id="title-20">Laboratory Evolution Experiments</title><p hwp:id="p-37">Evolution experiments to each antibiotic were performed in quadruplicate. Evolutions were performed using 1 mL BHI medium in 96-well plates with maximum volume 2 mL. Each day, populations were grown in at least three different antibiotic concentrations spanning both sub- and super-MIC doses. After 16-20 hours of incubation at 37°C, the well with the highest drug concentration that contained visual growth was propagated into 2 higher concentrations (typically a factor 2x and 4x increase in drug concentration) and 1 lower concentration to maintain a living mutant lineage (always half the concentration that most recently produced growth). A 1/200 dilution was used to inoculate the next day’s evolution plate, and the process was repeated for a total of 8 days of selection. On the final day of evolution all strains were stocked in 30 percent glycerol. Strains were then plated on a pure BHI plate and a single colony was selected for IC<sub>50</sub> determination. In the case of linezolid mutants, days 2, 4, and 6 were also stocked for further testing.</p></sec><sec id="s4c" hwp:id="sec-15"><label>C.</label><title hwp:id="title-21">Measuring Drug Resistance and Sensitivity</title><p hwp:id="p-38">Experiments to estimate IC<sub>50</sub> were performed in replicate in 96-well plates by exposing mutants to a drug gradient consisting of 6-14 points–one per well–typically in a linear dilution series prepared in BHI medium with a total volume of 205 uL (200 uL of BHI, 5 uL of 1.5OD cells) per well. After 20 hours of growth the optical density at 600 nm (0D600) was measured using an Enspire Multimodal Plate Reader (Perkin Elmer) with an automated 20-plate stacker assembly. This process was repeated for all 60 mutants as well as the wild-type, which was measured in replicates of 8.</p><p hwp:id="p-39">The optical density (OD600) measurements for each drug concentration were normalized by the OD600 in the absence of drug. To quantify drug resistance, the resulting dose response curve was fit to a Hill-like function <italic toggle="yes">f</italic>(<italic toggle="yes">x</italic>) = (1 + (<italic toggle="yes">x</italic>/<italic toggle="yes">K</italic>)<italic toggle="yes"><sup>h</sup></italic>)<sup>−1</sup> using nonlinear least squares fitting, where <italic toggle="yes">K</italic> is the half-maximal inhibitory concentration <italic toggle="yes">(IC<sub>50</sub></italic>) and h is a Hill coefficient describing the steepness of the dose-response relationship. A mutant strain was deemed collaterally sensitive (resistant) to an antibiotic if its IC<sub>50</sub> decreased (increased) by more than <italic toggle="yes">3σ<sub>WT</sub></italic>, where <italic toggle="yes">σ<sub>WT</sub></italic> is the uncertainty (standard error across replicates) of the IC<sub>50</sub> measured in the wild-type strain.</p></sec><sec id="s4d" hwp:id="sec-16"><label>D.</label><title hwp:id="title-22">Hierarchical clustering</title><p hwp:id="p-40">Hierarchical clustering was performed in Matlab using, as input, the collateral profiles <inline-formula hwp:id="inline-formula-10"><alternatives hwp:id="alternatives-10"><inline-graphic xlink:href="241075_inline26.gif" hwp:id="inline-graphic-10"/></alternatives></inline-formula> for each mutant. The distance between each pair of mutants was calculated using a correlation metric (Matlab function pdist with parameter ‘correlation’), and the linkage criteria was chosen to be the mean average linkage clustering.</p></sec><sec id="s4e" hwp:id="sec-17"><label>E.</label><title hwp:id="title-23">Markov decision process (MDP) model</title><p hwp:id="p-41">The MDP problem was solved using standard algorithms for MDP models. Briefly, the optimization was performed by first computing the optimal value (or cost) function-the optimal value (cost) corresponding to each state–using the well-established value iteration algorithm<sup><xref ref-type="bibr" rid="c53" hwp:id="xref-ref-53-2" hwp:rel-id="ref-53">53</xref></sup>. Given the optimal value (cost) function, the optimal policy is then given by the action that minimizes the optimal value (cost) function at the next time step.</p></sec></sec></body><back><ref-list hwp:id="ref-list-1"><title hwp:id="title-24">REFERENCES</title><ref id="c1" hwp:id="ref-1" hwp:rev-id="xref-ref-1-1"><label><sup>1</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.1" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-1"><string-name name-style="western" hwp:sortable="Boucher H. W."><surname>Boucher</surname>, <given-names>H. W.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Talbot G. H."><surname>Talbot</surname>, <given-names>G. H.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bradley J."><surname>Bradley</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Edwards J. E."><surname>Edwards</surname>, <given-names>J. E.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gilbert D."><surname>Gilbert</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rice L. B."><surname>Rice</surname>, <given-names>L. B.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Scheld M."><surname>Scheld</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Spellberg B."><surname>Spellberg</surname>, <given-names>B.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Bartlett J."><surname>Bartlett</surname>, <given-names>J.</given-names></string-name>, “<article-title hwp:id="article-title-2">Bad bugs, no drugs; no esape! an update from the infections diseases society of america</article-title>.,” <source hwp:id="source-1">Clin. Infect. Dis</source>. <volume>48</volume>, <fpage>1</fpage>–<lpage>12</lpage> (<year>2009</year>).</citation></ref><ref id="c2" hwp:id="ref-2"><label><sup>2</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.2" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-2"><string-name name-style="western" hwp:sortable="Goldberg D. E."><surname>Goldberg</surname>, <given-names>D. E.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Siliciana R."><surname>Siliciana</surname>, <given-names>R.</given-names>,</string-name> and Jr, W. R. J., “<article-title hwp:id="article-title-3">Outwitting evolution: Fighting drug-resistant tb, malaria, and hiv</article-title>.,” <source hwp:id="source-2">Cell</source> <volume>148</volume>, <fpage>1271</fpage>–<lpage>1283</lpage> (<year>2012</year>).</citation></ref><ref id="c3" hwp:id="ref-3"><label><sup>3</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.3" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-3"><string-name name-style="western" hwp:sortable="Pfaller A."><surname>Pfaller</surname>, <given-names>A.</given-names></string-name>, “<article-title hwp:id="article-title-4">Antifungal drug resistance: Mechanisms, epidemiology, and consequences for treatment</article-title>.,” <source hwp:id="source-3">Am. J. Med</source>. <volume>125</volume>, <fpage>S3</fpage>–<lpage>S13</lpage> (<year>2012</year>).</citation></ref><ref id="c4" hwp:id="ref-4"><label><sup>4</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.4" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-4"><string-name name-style="western" hwp:sortable="Raviglione M."><surname>Raviglione</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Marais B."><surname>Marais</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Floyd K."><surname>Floyd</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lonnoroth K."><surname>Lonnoroth</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Getahun H."><surname>Getahun</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Migliori G. B."><surname>Migliori</surname>, <given-names>G. B.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Harries A. D."><surname>Harries</surname>, <given-names>A. D.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Nunn P."><surname>Nunn</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lienhardt C."><surname>Lienhardt</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Graham S."><surname>Graham</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hakaya J."><surname>Hakaya</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Weyer K."><surname>Weyer</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cole S."><surname>Cole</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kaufmann S. H. E."><surname>Kaufmann</surname>, <given-names>S. H. E.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Zumla A."><surname>Zumla</surname>, <given-names>A.</given-names></string-name>, “<article-title hwp:id="article-title-5">Scaling up interentions to achieve global tuberculosis control: Progress and new developments</article-title>.,” <source hwp:id="source-4">Lancet</source> <volume>379</volume>, <fpage>1902</fpage>–<lpage>1913</lpage> (<year>2012</year>).</citation></ref><ref id="c5" hwp:id="ref-5"><label><sup>5</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.5" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-5"><string-name name-style="western" hwp:sortable="Borst P."><surname>Borst</surname>, <given-names>P.</given-names></string-name>, “<article-title hwp:id="article-title-6">Cancer drug pan-resistance: Pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persister or what?</article-title>.,” <source hwp:id="source-5">Open Biol. 2</source> (<year>2012</year>).</citation></ref><ref id="c6" hwp:id="ref-6" hwp:rev-id="xref-ref-6-1"><label><sup>6</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.6" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-6"><string-name name-style="western" hwp:sortable="Pluchino K. M."><surname>Pluchino</surname>, <given-names>K. M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hall M. D."><surname>Hall</surname>, <given-names>M. D.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Goldsborough A. S."><surname>Goldsborough</surname>, <given-names>A. S.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Callaghan R."><surname>Callaghan</surname>, <given-names>R.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Gotesman M. M."><surname>Gotesman</surname>, <given-names>M. M.</given-names></string-name>, “<article-title hwp:id="article-title-7">Collateral sensitivity as a strategy against cancer multidrug resistance</article-title>.,” <source hwp:id="source-6">Drug Resis. Updat</source>. <volume>15</volume>, <fpage>98</fpage>–<lpage>105</lpage> (<year>2012</year>).</citation></ref><ref id="c7" hwp:id="ref-7" hwp:rev-id="xref-ref-7-1"><label><sup>7</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.7" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-7"><string-name name-style="western" hwp:sortable="Martin R."><surname>Martin</surname>, <given-names>R.</given-names></string-name>, “<article-title hwp:id="article-title-8">Optimal control drug scheduling of cancer chemotherapy</article-title>.,” <source hwp:id="source-7">Journal of Antimicrobial Chemotherapy</source> <volume>28</volume>, <fpage>1113</fpage>–<lpage>1123</lpage> (<year>1992</year>).</citation></ref><ref id="c8" hwp:id="ref-8"><label><sup>8</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.8" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-8"><string-name name-style="western" hwp:sortable="Hansen E."><surname>Hansen</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Woods R. J."><surname>Woods</surname>, <given-names>R. J.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Read A. F."><surname>Read</surname>, <given-names>A. F.</given-names></string-name>, “<article-title hwp:id="article-title-9">How to use a chemotherapeutic agent when resistance to it threatens the patient</article-title>,” <source hwp:id="source-8">PLoS biology</source> <volume>15</volume>(<issue>2</issue>), <fpage>e2001110</fpage> (<year>2017</year>).</citation></ref><ref id="c9" hwp:id="ref-9" hwp:rev-id="xref-ref-9-1"><label><sup>9</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.9" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-9"><string-name name-style="western" hwp:sortable="Fischer A."><surname>Fischer</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Vázquez-García I."><surname>Vázquez-García</surname>, <given-names>I.</given-names></string-name>, and <string-name name-style="western" hwp:sortable="Mustonen V."><surname>Mustonen</surname>, <given-names>V.</given-names></string-name>, “<article-title hwp:id="article-title-10">The value of monitoring to control evolving populations</article-title>,” <source hwp:id="source-9">Proceedings of the National Academy of Sciences</source> <volume>112</volume>(<issue>4</issue>), <fpage>1007</fpage>–<lpage>1012</lpage> (<year>2015</year>).</citation></ref><ref id="c10" hwp:id="ref-10" hwp:rev-id="xref-ref-10-1"><label><sup>10</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.10" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-10"><string-name name-style="western" hwp:sortable="Feazel L. M."><surname>Feazel</surname>, <given-names>L. M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Malhotra A."><surname>Malhotra</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Perencevich E. N."><surname>Perencevich</surname>, <given-names>E. N.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kaboli P."><surname>Kaboli</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Diekemea D. J."><surname>Diekemea</surname>, <given-names>D. J.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Schweizer M. L."><surname>Schweizer</surname>, <given-names>M. L.</given-names></string-name>, “<article-title hwp:id="article-title-11">Effect of antibiotic stewardship programmes on <italic toggle="yes">clostridium difficile</italic> incidence: a systematic review and meta-analysis</article-title>.,” <source hwp:id="source-10">Journal of Antimicrobial Chemotherapy</source> <volume>69</volume>, <fpage>1748</fpage>–<lpage>1754</lpage> (<year>2014</year>).</citation></ref><ref id="c11" hwp:id="ref-11" hwp:rev-id="xref-ref-11-1"><label><sup>11</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.11" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-11"><string-name name-style="western" hwp:sortable="Smith D. L."><surname>Smith</surname>, <given-names>D. L.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Levin S. A."><surname>Levin</surname>, <given-names>S. A.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Laxminarayan R."><surname>Laxminarayan</surname>, <given-names>R.</given-names></string-name>, “<article-title hwp:id="article-title-12">Strategic interactions in multi-institutional epidemics of antibiotic resistance</article-title>.,” <source hwp:id="source-11">Proc. Natl. Acad. Sci. USA</source> <volume>102</volume>, <fpage>3153</fpage>–<lpage>3158</lpage> (<year>2004</year>).</citation></ref><ref id="c12" hwp:id="ref-12" hwp:rev-id="xref-ref-12-1"><label><sup>12</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.12" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-12"><string-name name-style="western" hwp:sortable="Bergstrom C. T."><surname>Bergstrom</surname>, <given-names>C. T.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lo M."><surname>Lo</surname>, <given-names>M.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Lipsitch M."><surname>Lipsitch</surname>, <given-names>M.</given-names></string-name>, “<article-title hwp:id="article-title-13">Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals</article-title>.,” <source hwp:id="source-12">Proc. Natl. Acad. Sci. USA</source> <volume>101</volume>, <fpage>13285</fpage>–<lpage>13290</lpage> (<year>2004</year>).</citation></ref><ref id="c13" hwp:id="ref-13"><label><sup>13</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.13" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-13"><string-name name-style="western" hwp:sortable="Brown E. M."><surname>Brown</surname>, <given-names>E. M.</given-names></string-name> and <string-name name-style="western" hwp:sortable="Nathwani D."><surname>Nathwani</surname>, <given-names>D.</given-names></string-name>, “<article-title hwp:id="article-title-14">Antibiotic cycling or rotation: a systemic review of the evidence of efficacy</article-title>.,” <source hwp:id="source-13">Journal of Antimicrobial Chemotherapy</source> <volume>55</volume>, <fpage>6</fpage>–<lpage>9</lpage> (<year>2005</year>).</citation></ref><ref id="c14" hwp:id="ref-14" hwp:rev-id="xref-ref-14-1"><label><sup>14</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.14" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-14"><string-name name-style="western" hwp:sortable="Nichol D."><surname>Nichol</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Jeavons P."><surname>Jeavons</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Fletcher A. G."><surname>Fletcher</surname>, <given-names>A. G.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bonomo R. A."><surname>Bonomo</surname>, <given-names>R. A.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Maini P. K."><surname>Maini</surname>, <given-names>P. K.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Paul J. L."><surname>Paul</surname>, <given-names>J. L.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gatenby R. A."><surname>Gatenby</surname>, <given-names>R. A.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Anderson A. R."><surname>Anderson</surname>, <given-names>A. R.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Scott J. G."><surname>Scott</surname>, <given-names>J. G.</given-names></string-name>, “<article-title hwp:id="article-title-15">Steering evolution with sequential therapy to prevent the emergence of bacterial antibiotic resistance</article-title>,” <source hwp:id="source-14">PLoS computational biology</source> <volume>11</volume>(<issue>9</issue>), <fpage>e1004493</fpage> (<year>2015</year>).</citation></ref><ref id="c15" hwp:id="ref-15" hwp:rev-id="xref-ref-15-1"><label><sup>15</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.15" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-15"><string-name name-style="western" hwp:sortable="Baym M."><surname>Baym</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lieberman T. D."><surname>Lieberman</surname>, <given-names>T. D.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kelsic E. D."><surname>Kelsic</surname>, <given-names>E. D.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chait R."><surname>Chait</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gross R."><surname>Gross</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Yelin I."><surname>Yelin</surname>, <given-names>I.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Kishony R."><surname>Kishony</surname>, <given-names>R.</given-names></string-name>, “<article-title hwp:id="article-title-16">Spatiotemporal microbial evolution on antibiotic landscapes</article-title>,” <source hwp:id="source-15">Science</source> <volume>353</volume>(<issue>6304</issue>), <fpage>1147</fpage>–<lpage>1151</lpage> (<year>2016</year>).</citation></ref><ref id="c16" hwp:id="ref-16" hwp:rev-id="xref-ref-16-1"><label><sup>16</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.16" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-16"><string-name name-style="western" hwp:sortable="Zhang Q."><surname>Zhang</surname>, <given-names>Q.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lambert G."><surname>Lambert</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Liao D."><surname>Liao</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kim H."><surname>Kim</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Robin K."><surname>Robin</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Tung C.-k."><surname>Tung</surname>, <given-names>C.-k.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pourmand N."><surname>Pourmand</surname>, <given-names>N.</given-names></string-name>, and <string-name name-style="western" hwp:sortable="Austin R. H."><surname>Austin</surname>, <given-names>R. H.</given-names></string-name>, “<article-title hwp:id="article-title-17">Acceleration of emergence of bacterial antibiotic resistance in connected microenvironments</article-title>,” <source hwp:id="source-16">Science</source> <volume>333</volume>(<issue>6050</issue>), <fpage>1764</fpage>–<lpage>1767</lpage> (<year>2011</year>).</citation></ref><ref id="c17" hwp:id="ref-17" hwp:rev-id="xref-ref-17-1"><label><sup>17</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.17" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-17"><string-name name-style="western" hwp:sortable="Yurtsev E. A."><surname>Yurtsev</surname>, <given-names>E. A.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chao H. X."><surname>Chao</surname>, <given-names>H. X.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Datta M. S."><surname>Datta</surname>, <given-names>M. S.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Artemova T."><surname>Artemova</surname>, <given-names>T.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Gore J."><surname>Gore</surname>, <given-names>J.</given-names></string-name>, “<article-title hwp:id="article-title-18">Bacterial cheating drives the population dynamics of cooperative antibiotic resistance plasmids</article-title>,” <source hwp:id="source-17">Molecular systems biology</source> <volume>9</volume>(<issue>1</issue>), <fpage>683</fpage> (<year>2013</year>).</citation></ref><ref id="c18" hwp:id="ref-18"><label><sup>18</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.18" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-18"><string-name name-style="western" hwp:sortable="Meredith H. R."><surname>Meredith</surname>, <given-names>H. R.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lopatkin A. J."><surname>Lopatkin</surname>, <given-names>A. J.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Anderson D. J."><surname>Anderson</surname>, <given-names>D. J.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="You L."><surname>You</surname>, <given-names>L.</given-names></string-name>, “<article-title hwp:id="article-title-19">Bacterial temporal dynamics enable optimal design of antibiotic treatment</article-title>,” <source hwp:id="source-18">PLoS computational biology</source> <volume>11</volume>(<issue>4</issue>), <fpage>e1004201</fpage> (<year>2015</year>).</citation></ref><ref id="c19" hwp:id="ref-19"><label><sup>19</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.19" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-19"><string-name name-style="western" hwp:sortable="Meredith H. R."><surname>Meredith</surname>, <given-names>H. R.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Srimani J. K."><surname>Srimani</surname>, <given-names>J. K.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lee A. J."><surname>Lee</surname>, <given-names>A. J.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lopatkin A. J."><surname>Lopatkin</surname>, <given-names>A. J.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="You L."><surname>You</surname>, <given-names>L.</given-names></string-name>, “<article-title hwp:id="article-title-20">Collective antibiotic tolerance: mechanisms, dynamics and intervention</article-title>,” <source hwp:id="source-19">Nature chemical biology</source> <volume>11</volume>(<issue>3</issue>), <fpage>182</fpage>–<lpage>188</lpage> (<year>2015</year>).</citation></ref><ref id="c20" hwp:id="ref-20" hwp:rev-id="xref-ref-20-1"><label><sup>20</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.20" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-20"><string-name name-style="western" hwp:sortable="Vega N. M."><surname>Vega</surname>, <given-names>N. M.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Gore J."><surname>Gore</surname>, <given-names>J.</given-names></string-name>, “<article-title hwp:id="article-title-21">Collective antibiotic resistance: mechanisms and implications</article-title>,” <source hwp:id="source-20">Current opinion in microbiology</source> <volume>21</volume>, <fpage>28</fpage>–<lpage>34</lpage> (<year>2014</year>).</citation></ref><ref id="c21" hwp:id="ref-21" hwp:rev-id="xref-ref-21-1"><label><sup>21</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.21" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-21"><string-name name-style="western" hwp:sortable="Balaban N. Q."><surname>Balaban</surname>, <given-names>N. Q.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Merrin J."><surname>Merrin</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chait R."><surname>Chait</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kowalik L."><surname>Kowalik</surname>, <given-names>L.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Leibler S."><surname>Leibler</surname>, <given-names>S.</given-names></string-name>, “<article-title hwp:id="article-title-22">Bacterial persistence as a phenotypic switch</article-title>,” <source hwp:id="source-21">Science</source> <volume>305</volume>(<issue>5690</issue>), <fpage>1622</fpage>–<lpage>1625</lpage> (<year>2004</year>).</citation></ref><ref id="c22" hwp:id="ref-22"><label><sup>22</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.22" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-22"><string-name name-style="western" hwp:sortable="Tan C."><surname>Tan</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Smith R. P."><surname>Smith</surname>, <given-names>R. P.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Srimani J. K."><surname>Srimani</surname>, <given-names>J. K.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Riccione K. A."><surname>Riccione</surname>, <given-names>K. A.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Prasada S."><surname>Prasada</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kuehn M."><surname>Kuehn</surname>, <given-names>M.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="You L."><surname>You</surname>, <given-names>L.</given-names></string-name>, “<article-title hwp:id="article-title-23">The inoculum effect and band-pass bacterial response to periodic antibiotic treatment</article-title>,” <source hwp:id="source-22">Molecular systems biology</source> <volume>8</volume>(<issue>1</issue>), <fpage>617</fpage> (<year>2012</year>).</citation></ref><ref id="c23" hwp:id="ref-23" hwp:rev-id="xref-ref-23-1"><label><sup>23</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.23" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-23"><string-name name-style="western" hwp:sortable="Karslake J."><surname>Karslake</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Maltas J."><surname>Maltas</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Brumm P."><surname>Brumm</surname>, <given-names>P.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Wood K. B."><surname>Wood</surname>, <given-names>K. B.</given-names></string-name>, “<article-title hwp:id="article-title-24">Population density modulates drug inhibition and gives rise to potential bistability of treatment outcomes for bacterial infections</article-title>,” <source hwp:id="source-23">PLoS computational biology</source> <volume>12</volume>(<issue>10</issue>), <fpage>e1005098</fpage> (<year>2016</year>).</citation></ref><ref id="c24" hwp:id="ref-24" hwp:rev-id="xref-ref-24-1"><label><sup>24</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.24" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-24"><string-name name-style="western" hwp:sortable="Torella J. P."><surname>Torella</surname>, <given-names>J. P.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chait R."><surname>Chait</surname>, <given-names>R.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Kishony R."><surname>Kishony</surname>, <given-names>R.</given-names></string-name>, “<article-title hwp:id="article-title-25">Optimal drug synergy in antimicrobial treatments</article-title>.,” <source hwp:id="source-24">PlOS Comput. Biol.</source>. <volume>6</volume> (<year>2010</year>).</citation></ref><ref id="c25" hwp:id="ref-25"><label><sup>25</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.25" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-25"><string-name name-style="western" hwp:sortable="Michel J."><surname>Michel</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Yeh P. J."><surname>Yeh</surname>, <given-names>P. J.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chait R. Jr"><surname>Chait</surname>, <given-names>R.</given-names>, <suffix>Jr</suffix></string-name>, <collab hwp:id="collab-1">R. C. M.</collab>, and <string-name name-style="western" hwp:sortable="Kishony R."><surname>Kishony</surname>, <given-names>R.</given-names></string-name>, “<article-title hwp:id="article-title-26">Drug interactions modulate the potential for evolution of resistance</article-title>.,” <source hwp:id="source-25">Proc. Natl. Acad. Sci. USA</source> <volume>105</volume>, <fpage>14918</fpage>–<lpage>14923</lpage> (<year>2008</year>).</citation></ref><ref id="c26" hwp:id="ref-26"><label><sup>26</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.26" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-26"><string-name name-style="western" hwp:sortable="Hegreness M."><surname>Hegreness</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Shoresh N."><surname>Shoresh</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Damian D."><surname>Damian</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hartl D."><surname>Hartl</surname>, <given-names>D.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Kishony R."><surname>Kishony</surname>, <given-names>R.</given-names></string-name>, “<article-title hwp:id="article-title-27">Accelerated evolution of resistance in multi-drug environments</article-title>.,” <source hwp:id="source-26">Proc. Natl. Acad. Sci. USA</source> <volume>105</volume>, <fpage>13977</fpage>–<lpage>13981</lpage> (<year>2008</year>).</citation></ref><ref id="c27" hwp:id="ref-27"><label><sup>27</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.27" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-27"><string-name name-style="western" hwp:sortable="Chait R."><surname>Chait</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Craney A."><surname>Craney</surname>, <given-names>A.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Kishony R."><surname>Kishony</surname>, <given-names>R.</given-names></string-name>, “<article-title hwp:id="article-title-28">Antibiotic interactions that select against resistance</article-title>,” <source hwp:id="source-27">Nature</source> <volume>446</volume>(<issue>7136</issue>), <fpage>668</fpage> (<year>2007</year>).</citation></ref><ref id="c28" hwp:id="ref-28"><label><sup>28</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.28" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-28"><string-name name-style="western" hwp:sortable="Baym M."><surname>Baym</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Stone L. K."><surname>Stone</surname>, <given-names>L. K.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Kishony R."><surname>Kishony</surname>, <given-names>R.</given-names></string-name>, “<article-title hwp:id="article-title-29">Multidrug evolutionary strategies to reverse antibiotic resistance</article-title>,” <source hwp:id="source-28">Science</source> <volume>351</volume>(<issue>6268</issue>), <fpage>aad3292</fpage> (<year>2016</year>).</citation></ref><ref id="c29" hwp:id="ref-29"><label><sup>29</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.29" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-29"><string-name name-style="western" hwp:sortable="Wood K."><surname>Wood</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Nishida S."><surname>Nishida</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sontag E. D."><surname>Sontag</surname>, <given-names>E. D.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Cluzel P."><surname>Cluzel</surname>, <given-names>P.</given-names></string-name>, “<article-title hwp:id="article-title-30">Mechanism-independent method for predicting response to multidrug combinations in bacteria</article-title>,” <source hwp:id="source-29">Proceedings of the National Academy of Sciences</source> <volume>109</volume>(<issue>30</issue>), <fpage>12254</fpage>–<lpage>12259</lpage> (<year>2012</year>).</citation></ref><ref id="c30" hwp:id="ref-30"><label><sup>30</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.30" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-30"><string-name name-style="western" hwp:sortable="Zimmer A."><surname>Zimmer</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Katzir I."><surname>Katzir</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dekel E."><surname>Dekel</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mayo A. E."><surname>Mayo</surname>, <given-names>A. E.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Alon U."><surname>Alon</surname>, <given-names>U.</given-names></string-name>, “<article-title hwp:id="article-title-31">Prediction of multidimensional drug dose responses based on measurements of drug pairs</article-title>,” <source hwp:id="source-30">Proceedings of the National Academy of Sciences</source> <volume>113</volume>(<issue>37</issue>), <fpage>10442</fpage>–<lpage>10447</lpage> (<year>2016</year>).</citation></ref><ref id="c31" hwp:id="ref-31" hwp:rev-id="xref-ref-31-1"><label><sup>31</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.31" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-31"><string-name name-style="western" hwp:sortable="Zimmer A."><surname>Zimmer</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Tendler A."><surname>Tendler</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Katzir I."><surname>Katzir</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mayo A."><surname>Mayo</surname>, <given-names>A.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Alon U."><surname>Alon</surname>, <given-names>U.</given-names></string-name>, “<article-title hwp:id="article-title-32">Prediction of drug cocktail effects when the number of measurements is limited</article-title>,” <source hwp:id="source-31">PLoS biology</source> <volume>15</volume>(<issue>10</issue>), <fpage>e2002518</fpage> (<year>2017</year>).</citation></ref><ref id="c32" hwp:id="ref-32" hwp:rev-id="xref-ref-32-1"><label><sup>32</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.32" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-32"><string-name name-style="western" hwp:sortable="de Evgrafov M. R."><surname>de Evgrafov</surname>, <given-names>M. R.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gumpert H."><surname>Gumpert</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Munck C."><surname>Munck</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Thomsen T. T."><surname>Thomsen</surname>, <given-names>T. T.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Sommer M. O. A."><surname>Sommer</surname>, <given-names>M. O. A.</given-names></string-name>, “<article-title hwp:id="article-title-33">Collateral resistance and sensitivity modulate evolution in high-level resistance to drug combination treatment in <italic toggle="yes">staphylococcus aureus</italic></article-title>.,” <source hwp:id="source-32">Mol. Biol. Evol</source>. <volume>32</volume>, <fpage>1175</fpage>–<lpage>1185</lpage> (<year>2015</year>).</citation></ref><ref id="c33" hwp:id="ref-33"><label><sup>33</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.33" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-33"><string-name name-style="western" hwp:sortable="Oz T."><surname>Oz</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Guvenek A."><surname>Guvenek</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Yildiz S."><surname>Yildiz</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Karaboga E."><surname>Karaboga</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Tamer Y. T."><surname>Tamer</surname>, <given-names>Y. T.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mumcuyan N."><surname>Mumcuyan</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ozan V. B."><surname>Ozan</surname>, <given-names>V. B.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Senturk G. H."><surname>Senturk</surname>, <given-names>G. H.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cokol M."><surname>Cokol</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Yeh P."><surname>Yeh</surname>, <given-names>P.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Toprak E."><surname>Toprak</surname>, <given-names>E.</given-names></string-name>, “<article-title hwp:id="article-title-34">Strength of selection pressure is an important parameter contributing to the complexity of antibiotic resistance evolution</article-title>.,” <source hwp:id="source-33">Mol. Biol. Evol</source>. <volume>31</volume>, <fpage>2387</fpage>–<lpage>2401</lpage> (<year>2014</year>).</citation></ref><ref id="c34" hwp:id="ref-34"><label><sup>34</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.34" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-34"><string-name name-style="western" hwp:sortable="Lazar V."><surname>Lazar</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Nagy I."><surname>Nagy</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Spohn R."><surname>Spohn</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Csorgo B."><surname>Csorgo</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gyorkei A."><surname>Gyorkei</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Nyerges A."><surname>Nyerges</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Horvath B."><surname>Horvath</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Voros A."><surname>Voros</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Busa-Fekete R."><surname>Busa-Fekete</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hrtyan M."><surname>Hrtyan</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bogos B."><surname>Bogos</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mehi O."><surname>Mehi</surname>, <given-names>O.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Fekete G."><surname>Fekete</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Szappanos B."><surname>Szappanos</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kegl B."><surname>Kegl</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Papp B."><surname>Papp</surname>, <given-names>B.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Pal C."><surname>Pal</surname>, <given-names>C.</given-names></string-name>, “<article-title hwp:id="article-title-35">Genome-wide analysis captures the determinants of the antibiotic cross-resistance interaction network</article-title>.,” <source hwp:id="source-34">Nat. Commun</source>. <volume>5</volume> (<year>2014</year>).</citation></ref><ref id="c35" hwp:id="ref-35" hwp:rev-id="xref-ref-35-1"><label><sup>35</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.35" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-35"><string-name name-style="western" hwp:sortable="Lazar V."><surname>Lazar</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Singh G. P."><surname>Singh</surname>, <given-names>G. P.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Spohn R."><surname>Spohn</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Nagy I."><surname>Nagy</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Horvath B."><surname>Horvath</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hrtyan M."><surname>Hrtyan</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Busa-Fekete R."><surname>Busa-Fekete</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bogos B."><surname>Bogos</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mehi O."><surname>Mehi</surname>, <given-names>O.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Csorgo B."><surname>Csorgo</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Posfai G."><surname>Posfai</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Fekete G."><surname>Fekete</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Szappanos B."><surname>Szappanos</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kegl B."><surname>Kegl</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Papp B."><surname>Papp</surname>, <given-names>B.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Pal C."><surname>Pal</surname>, <given-names>C.</given-names></string-name>, “<article-title hwp:id="article-title-36">Bacterial evolution and antibiotic hypersensitivity</article-title>.,” <source hwp:id="source-35">Mol. Syst. Biol</source>. <volume>9</volume> (<year>2013</year>).</citation></ref><ref id="c36" hwp:id="ref-36" hwp:rev-id="xref-ref-36-1"><label><sup>36</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.36" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-36"><string-name name-style="western" hwp:sortable="Shoval O."><surname>Shoval</surname>, <given-names>O.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sheftel H."><surname>Sheftel</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Shinar G."><surname>Shinar</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hart Y."><surname>Hart</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ramote O."><surname>Ramote</surname>, <given-names>O.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mayo A."><surname>Mayo</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dekel E."><surname>Dekel</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kavanagh K."><surname>Kavanagh</surname>, <given-names>K.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Alon U."><surname>Alon</surname>, <given-names>U.</given-names></string-name>, “<article-title hwp:id="article-title-37">Evolutionary trade-offs, pareto optimality, and the geometry of phenotype space</article-title>,” <source hwp:id="source-36">Science</source> <volume>336</volume>(<issue>6085</issue>), <fpage>1157</fpage>–<lpage>1160</lpage> (<year>2012</year>).</citation></ref><ref id="c37" hwp:id="ref-37" hwp:rev-id="xref-ref-37-1"><label><sup>37</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.37" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-37"><string-name name-style="western" hwp:sortable="Hart Y."><surname>Hart</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sheftel H."><surname>Sheftel</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hausser J."><surname>Hausser</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Szekely P."><surname>Szekely</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ben-Moshe N. B."><surname>Ben-Moshe</surname>, <given-names>N. B.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Korem Y."><surname>Korem</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Tendler A."><surname>Tendler</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mayo A. E."><surname>Mayo</surname>, <given-names>A. E.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Alon U."><surname>Alon</surname>, <given-names>U.</given-names></string-name>, “<article-title hwp:id="article-title-38">Inferring biological tasks using pareto analysis of highdimensional data</article-title>,” <source hwp:id="source-37">Nature methods</source> <volume>12</volume>(<issue>3</issue>), <fpage>233</fpage>–<lpage>235</lpage> (<year>2015</year>).</citation></ref><ref id="c38" hwp:id="ref-38" hwp:rev-id="xref-ref-38-1 xref-ref-38-2"><label><sup>38</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.38" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-38"><string-name name-style="western" hwp:sortable="Imamovic L."><surname>Imamovic</surname>, <given-names>L.</given-names></string-name> and <string-name name-style="western" hwp:sortable="Sommer M. O. A."><surname>Sommer</surname>, <given-names>M. O. A.</given-names></string-name>, “<article-title hwp:id="article-title-39">Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development</article-title>.,” <source hwp:id="source-38">Sci. Transl. Med</source> <volume>5</volume>, <fpage>204ra132</fpage> (<year>2013</year>).</citation></ref><ref id="c39" hwp:id="ref-39" hwp:rev-id="xref-ref-39-1"><label><sup>39</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.39" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-39"><string-name name-style="western" hwp:sortable="Kim S."><surname>Kim</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lieberman T. D."><surname>Lieberman</surname>, <given-names>T. D.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Kishony R."><surname>Kishony</surname>, <given-names>R.</given-names></string-name>, “<article-title hwp:id="article-title-40">Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance</article-title>.,” <source hwp:id="source-39">Proc. Natl. Acad. Sci. USA</source> <volume>111</volume>, <fpage>1449414499</fpage> (<year>2014</year>).</citation></ref><ref id="c40" hwp:id="ref-40" hwp:rev-id="xref-ref-40-1"><label><sup>40</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.40" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-40"><string-name name-style="western" hwp:sortable="Yoshida M."><surname>Yoshida</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Reyes S. G."><surname>Reyes</surname>, <given-names>S. G.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Tsudo S."><surname>Tsudo</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Horinouchi T."><surname>Horinouchi</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Furusawa C."><surname>Furusawa</surname>, <given-names>C.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Cronin L."><surname>Cronin</surname>, <given-names>L.</given-names></string-name>, “<article-title hwp:id="article-title-41">Time-programmable dosing allows the manipulation, suppression and reversal of antibiotic drug resistance <italic toggle="yes">in vitro</italic></article-title>.,” <source hwp:id="source-40">Nat. Commun</source>. <volume>8</volume> (<year>2017</year>).</citation></ref><ref id="c41" hwp:id="ref-41" hwp:rev-id="xref-ref-41-1"><label><sup>41</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.41" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-41"><string-name name-style="western" hwp:sortable="Munck C."><surname>Munck</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gumpert H. K."><surname>Gumpert</surname>, <given-names>H. K.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wallin A. I. N."><surname>Wallin</surname>, <given-names>A. I. N.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wang H. H."><surname>Wang</surname>, <given-names>H. H.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Sommer M. O. A."><surname>Sommer</surname>, <given-names>M. O. A.</given-names></string-name>, “<article-title hwp:id="article-title-42">Prediction of resistance development against drug components by collateral responses to component drugs</article-title>.,” <source hwp:id="source-41">Sci. Transl. Med</source> <volume>6</volume>, <fpage>262ra156</fpage> (<year>2014</year>).</citation></ref><ref id="c42" hwp:id="ref-42" hwp:rev-id="xref-ref-42-1 xref-ref-42-2"><label><sup>42</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.42" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-42"><string-name name-style="western" hwp:sortable="Barbosa C."><surname>Barbosa</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Trebosc V."><surname>Trebosc</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kemmer C."><surname>Kemmer</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rosenstiel P."><surname>Rosenstiel</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Beardmore R."><surname>Beardmore</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Schulenburg H."><surname>Schulenburg</surname>, <given-names>H.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Jansen G."><surname>Jansen</surname>, <given-names>G.</given-names></string-name>, “<article-title hwp:id="article-title-43">Alternative evolutionary paths to bacterial antibiotic resistance cause distinct collateral effects</article-title>.,” <source hwp:id="source-42">Mol. Biol. Evol</source>. <volume>34</volume>, <fpage>22292244</fpage> (<year>2017</year>).</citation></ref><ref id="c43" hwp:id="ref-43" hwp:rev-id="xref-ref-43-1 xref-ref-43-2 xref-ref-43-3 xref-ref-43-4"><label><sup>43</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.43" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-43"><string-name name-style="western" hwp:sortable="Dhawan A."><surname>Dhawan</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Nichol D."><surname>Nichol</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kinose F."><surname>Kinose</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Abazeed M. E."><surname>Abazeed</surname>, <given-names>M. E.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Marusyk A."><surname>Marusyk</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Haura E. B."><surname>Haura</surname>, <given-names>E. B.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Scott J. G."><surname>Scott</surname>, <given-names>J. G.</given-names></string-name>, “<article-title hwp:id="article-title-44">Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in alk mutated non-small cell lung cancer</article-title>,” <source hwp:id="source-43">Scientific Reports</source> <volume>7</volume> (<year>2017</year>).</citation></ref><ref id="c44" hwp:id="ref-44" hwp:rev-id="xref-ref-44-1 xref-ref-44-2"><label><sup>44</sup></label><citation publication-type="other" citation-type="journal" ref:id="241075v2.44" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-44"><string-name name-style="western" hwp:sortable="Nichol D."><surname>Nichol</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rutter J."><surname>Rutter</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bryant C."><surname>Bryant</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Jeavons P."><surname>Jeavons</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Anderson A."><surname>Anderson</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bonomo R."><surname>Bonomo</surname>, <given-names>R.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Scott J."><surname>Scott</surname>, <given-names>J.</given-names></string-name>, “<article-title hwp:id="article-title-45">Collateral sensitivity is contingent on the repeatability of evolution</article-title>,” <source hwp:id="source-44">bioRxiv</source> (<year>2017</year>).</citation></ref><ref id="c45" hwp:id="ref-45" hwp:rev-id="xref-ref-45-1"><label><sup>45</sup></label><citation publication-type="other" citation-type="journal" ref:id="241075v2.45" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-45"><string-name name-style="western" hwp:sortable="Clewell D. B."><surname>Clewell</surname>, <given-names>D. B.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gilmore M. S."><surname>Gilmore</surname>, <given-names>M. S.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ike Y."><surname>Ike</surname>, <given-names>Y.</given-names></string-name>, and <string-name name-style="western" hwp:sortable="Shankar N."><surname>Shankar</surname>, <given-names>N.</given-names></string-name>, <source hwp:id="source-45">[Enterococci: from commensals to leading causes of drug resistant infection], Massachusetts Eye and Ear Infirmary</source> (<year>2014</year>).</citation></ref><ref id="c46" hwp:id="ref-46"><label><sup>46</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.46" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-46"><string-name name-style="western" hwp:sortable="Donlan R. M."><surname>Donlan</surname>, <given-names>R. M.</given-names></string-name>, “<article-title hwp:id="article-title-46">Biofilms and device-associated infections</article-title>.,” <source hwp:id="source-46">Emerging infectious diseases</source> <volume>7</volume>(<issue>2</issue>), <fpage>277</fpage> (<year>2001</year>).</citation></ref><ref id="c47" hwp:id="ref-47"><label><sup>47</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.47" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-47"><string-name name-style="western" hwp:sortable="O’Driscoll T."><surname>O’Driscoll</surname>, <given-names>T.</given-names></string-name> and <string-name name-style="western" hwp:sortable="Crank C. W."><surname>Crank</surname>, <given-names>C. W.</given-names></string-name>, “<article-title hwp:id="article-title-47">Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations and optimal management</article-title>.,” <source hwp:id="source-47">Drug Resis. Updat</source>. <volume>8</volume>, <fpage>217</fpage>–<lpage>230</lpage> (<year>2015</year>).</citation></ref><ref id="c48" hwp:id="ref-48" hwp:rev-id="xref-ref-48-1"><label><sup>48</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.48" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-48"><string-name name-style="western" hwp:sortable="Cetinkaya Y."><surname>Cetinkaya</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Falk P."><surname>Falk</surname>, <given-names>P.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Mayhall C. G."><surname>Mayhall</surname>, <given-names>C. G.</given-names></string-name>, “<article-title hwp:id="article-title-48">Vancomycin resistant enterococci</article-title>.,” <source hwp:id="source-48">Clin. Microbiol. Rev</source>. <volume>13</volume>, <fpage>686</fpage>–<lpage>707</lpage> (<year>2000</year>).</citation></ref><ref id="c49" hwp:id="ref-49" hwp:rev-id="xref-ref-49-1"><label><sup>49</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.49" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-49"><string-name name-style="western" hwp:sortable="Kelesidis T."><surname>Kelesidis</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Humphries R."><surname>Humphries</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Uslan D. Z."><surname>Uslan</surname>, <given-names>D. Z.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Pegues D. A."><surname>Pegues</surname>, <given-names>D. A.</given-names></string-name>, “<article-title hwp:id="article-title-49">Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians</article-title>,” <source hwp:id="source-49">Clinical Infectious Diseases</source> <volume>52</volume>(<issue>2</issue>), <fpage>228</fpage>–<lpage>234</lpage> (<year>2011</year>).</citation></ref><ref id="c50" hwp:id="ref-50" hwp:rev-id="xref-ref-50-1"><label><sup>50</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.50" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-50"><string-name name-style="western" hwp:sortable="Tran T. T."><surname>Tran</surname>, <given-names>T. T.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Munita J. M."><surname>Munita</surname>, <given-names>J. M.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Arias C. A."><surname>Arias</surname>, <given-names>C. A.</given-names></string-name>, “<article-title hwp:id="article-title-50">Mechanisms of drug resistance: daptomycin resistance</article-title>,” <source hwp:id="source-50">Annals of the New York Academy of Sciences</source> <volume>1354</volume>(<issue>1</issue>), <fpage>32</fpage>–<lpage>53</lpage> (<year>2015</year>).</citation></ref><ref id="c51" hwp:id="ref-51" hwp:rev-id="xref-ref-51-1 xref-ref-51-2"><label><sup>51</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.51" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-51"><string-name name-style="western" hwp:sortable="Zhao B."><surname>Zhao</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sedlak J. C."><surname>Sedlak</surname>, <given-names>J. C.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Srinivas R."><surname>Srinivas</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Creixell P."><surname>Creixell</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pritchard J. R."><surname>Pritchard</surname>, <given-names>J. R.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Tidor B."><surname>Tidor</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lauffenburger D. A."><surname>Lauffenburger</surname>, <given-names>D. A.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Hemann M. T."><surname>Hemann</surname>, <given-names>M. T.</given-names></string-name>, “<article-title hwp:id="article-title-51">Exploiting temporal collateral sensitivity in tumor clonal evolution</article-title>.,” <source hwp:id="source-51">Cell</source>. <volume>165</volume>, <fpage>1</fpage>–<lpage>13</lpage> (<year>2016</year>).</citation></ref><ref id="c52" hwp:id="ref-52" hwp:rev-id="xref-ref-52-1"><label><sup>52</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.52" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-52"><string-name name-style="western" hwp:sortable="Yeh P."><surname>Yeh</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Tschumi A. I."><surname>Tschumi</surname>, <given-names>A. I.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Kishony R."><surname>Kishony</surname>, <given-names>R.</given-names></string-name>, “<article-title hwp:id="article-title-52">Functional classification of drugs by properties of their pairwise interactions</article-title>.,” <source hwp:id="source-52">Nature Genetics</source> <volume>38</volume>, <fpage>489</fpage>–<lpage>494</lpage> (<year>2006</year>).</citation></ref><ref id="c53" hwp:id="ref-53" hwp:rev-id="xref-ref-53-1 xref-ref-53-2"><label><sup>53</sup></label><citation publication-type="book" citation-type="book" ref:id="241075v2.53" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-53"><string-name name-style="western" hwp:sortable="Feinberg E. A."><surname>Feinberg</surname>, <given-names>E. A.</given-names></string-name> and <string-name name-style="western" hwp:sortable="Shwartz A."><surname>Shwartz</surname>, <given-names>A.</given-names></string-name>, <source hwp:id="source-53">[Handbook of Markov decision processes: methods and applications]</source>, vol. <volume>40</volume>, <publisher-name>Springer Science &amp; Business Media</publisher-name> (<year>2012</year>).</citation></ref><ref id="c54" hwp:id="ref-54" hwp:rev-id="xref-ref-54-1"><label><sup>54</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.54" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-54"><string-name name-style="western" hwp:sortable="Humphries R. M."><surname>Humphries</surname>, <given-names>R. M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pollett S."><surname>Pollett</surname>, <given-names>S.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Sakoulas G."><surname>Sakoulas</surname>, <given-names>G.</given-names></string-name>, “<article-title hwp:id="article-title-53">A current perspective on daptomycin for the clinical microbiologist</article-title>.,” <source hwp:id="source-54">Clin. Microbiol. Rev</source>. <volume>26</volume>, <fpage>759</fpage>–<lpage>780</lpage> (<year>2013</year>).</citation></ref><ref id="c55" hwp:id="ref-55" hwp:rev-id="xref-ref-55-1"><label><sup>55</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.55" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-55"><string-name name-style="western" hwp:sortable="Yu W."><surname>Yu</surname>, <given-names>W.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hallinen K. M."><surname>Hallinen</surname>, <given-names>K. M.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Wood K. B."><surname>Wood</surname>, <given-names>K. B.</given-names></string-name>, “<article-title hwp:id="article-title-54">Interplay between antibiotic efficacy and drug-induced lysis underlies enhanced biofilm formation at subinhibitory drug concentrations</article-title>,” <source hwp:id="source-55">Antimicrobial agents and chemotherapy</source> <volume>62</volume>(<issue>1</issue>), <fpage>e01603</fpage>–<lpage>17</lpage> (<year>2018</year>).</citation></ref><ref id="c56" hwp:id="ref-56" hwp:rev-id="xref-ref-56-1"><label><sup>56</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.56" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-56"><string-name name-style="western" hwp:sortable="Martin M."><surname>Martin</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hölscher T."><surname>Hölscher</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dragoš A."><surname>Dragoš</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cooper V. S."><surname>Cooper</surname>, <given-names>V. S.</given-names></string-name>, and <string-name name-style="western" hwp:sortable="Kovács Á. T."><surname>Kovács</surname>, <given-names>Á. T.</given-names></string-name>, “<article-title hwp:id="article-title-55">Laboratory evolution of microbial interactions in bacterial biofilms</article-title>,” <source hwp:id="source-56">Journal of bacteriology</source> <volume>198</volume>(<issue>19</issue>), <fpage>2564</fpage>–<lpage>2571</lpage> (<year>2016</year>).</citation></ref><ref id="c57" hwp:id="ref-57" hwp:rev-id="xref-ref-57-1"><label><sup>57</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.57" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-57"><string-name name-style="western" hwp:sortable="Steenackers H. P."><surname>Steenackers</surname>, <given-names>H. P.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Parijs I."><surname>Parijs</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Foster K. R."><surname>Foster</surname>, <given-names>K. R.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Vanderleyden J."><surname>Vanderleyden</surname>, <given-names>J.</given-names></string-name>, “<article-title hwp:id="article-title-56">Experimental evolution in biofilm populations</article-title>,” <source hwp:id="source-57">FEMS microbiology reviews</source> <volume>40</volume>(<issue>3</issue>), <fpage>373</fpage>–<lpage>397</lpage> (<year>2016</year>).</citation></ref><ref id="c58" hwp:id="ref-58" hwp:rev-id="xref-ref-58-1"><label><sup>58</sup></label><citation publication-type="journal" citation-type="journal" ref:id="241075v2.58" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-58"><string-name name-style="western" hwp:sortable="Sahm D. F."><surname>Sahm</surname>, <given-names>D. F.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kissinger J."><surname>Kissinger</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gilmore M. S."><surname>Gilmore</surname>, <given-names>M. S.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Murray P. R."><surname>Murray</surname>, <given-names>P. R.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mulder R."><surname>Mulder</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Solliday J."><surname>Solliday</surname>, <given-names>J.</given-names>,</string-name> and <string-name name-style="western" hwp:sortable="Clarke B."><surname>Clarke</surname>, <given-names>B.</given-names></string-name>, “<article-title hwp:id="article-title-57">In vitro susceptibility studies of vancomycin-resistant enterococcus faecalis</article-title>,” <source hwp:id="source-58">Antimicrobial Agents and Chemotherapy</source> <volume>33</volume>, <fpage>1588</fpage>–<lpage>1591</lpage> (Sept. <year>1989</year>).</citation></ref></ref-list></back></article>
